WO2017084012A1 - Acoustic material weighing and manipulation - Google Patents
Acoustic material weighing and manipulation Download PDFInfo
- Publication number
- WO2017084012A1 WO2017084012A1 PCT/CN2015/094697 CN2015094697W WO2017084012A1 WO 2017084012 A1 WO2017084012 A1 WO 2017084012A1 CN 2015094697 W CN2015094697 W CN 2015094697W WO 2017084012 A1 WO2017084012 A1 WO 2017084012A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acoustic
- weight
- determining
- agents
- particle
- Prior art date
Links
- 238000005303 weighing Methods 0.000 title description 9
- 239000012814 acoustic material Substances 0.000 title description 2
- 239000000463 material Substances 0.000 claims abstract description 222
- 238000000034 method Methods 0.000 claims abstract description 104
- 239000002245 particle Substances 0.000 claims abstract description 100
- 238000005339 levitation Methods 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 239000007787 solid Substances 0.000 claims abstract description 28
- 239000007788 liquid Substances 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 26
- 239000002775 capsule Substances 0.000 claims description 25
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 22
- 230000003287 optical effect Effects 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 14
- 239000011343 solid material Substances 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 9
- 238000004220 aggregation Methods 0.000 claims description 6
- 230000002776 aggregation Effects 0.000 claims description 6
- 239000003708 ampul Substances 0.000 claims description 6
- 230000005684 electric field Effects 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000543 intermediate Substances 0.000 claims description 6
- 239000011344 liquid material Substances 0.000 claims description 6
- 239000000902 placebo Substances 0.000 claims description 6
- 229940068196 placebo Drugs 0.000 claims description 6
- 210000003850 cellular structure Anatomy 0.000 claims description 5
- 239000013583 drug formulation Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 238000003384 imaging method Methods 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 5
- 239000002417 nutraceutical Substances 0.000 claims description 5
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 239000000693 micelle Substances 0.000 claims description 4
- 239000011877 solvent mixture Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 239000012857 radioactive material Substances 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 230000003313 weakening effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 239000004480 active ingredient Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 21
- 230000000699 topical effect Effects 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- -1 allergenics Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 229940125681 anticonvulsant agent Drugs 0.000 description 13
- 239000001961 anticonvulsive agent Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000002924 anti-infective effect Effects 0.000 description 11
- 229960005475 antiinfective agent Drugs 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 239000003381 stabilizer Substances 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 238000000576 coating method Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 239000003416 antiarrhythmic agent Substances 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 229940014259 gelatin Drugs 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000003288 anthiarrhythmic effect Effects 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000003193 general anesthetic agent Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 229940035674 anesthetics Drugs 0.000 description 4
- 230000003474 anti-emetic effect Effects 0.000 description 4
- 239000002111 antiemetic agent Substances 0.000 description 4
- 229940125715 antihistaminic agent Drugs 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 239000003430 antimalarial agent Substances 0.000 description 4
- 239000002876 beta blocker Substances 0.000 description 4
- 229940097320 beta blocking agent Drugs 0.000 description 4
- 229940124630 bronchodilator Drugs 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000000193 iodinated contrast media Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 150000002960 penicillins Chemical class 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 239000003451 thiazide diuretic agent Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000674 adrenergic antagonist Substances 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000001078 anti-cholinergic effect Effects 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 229940125683 antiemetic agent Drugs 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940125688 antiparkinson agent Drugs 0.000 description 3
- 239000000939 antiparkinson agent Substances 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000000168 bronchodilator agent Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000000850 decongestant Substances 0.000 description 3
- 229940124581 decongestants Drugs 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229940030606 diuretics Drugs 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000003163 gonadal steroid hormone Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 239000003158 myorelaxant agent Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N pentadecanoic acid Chemical compound CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 239000003732 agents acting on the eye Substances 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000000078 anti-malarial effect Effects 0.000 description 2
- 230000002682 anti-psoriatic effect Effects 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 229940030999 antipsoriatics Drugs 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- 229940121383 antituberculosis agent Drugs 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000002617 bone density conservation agent Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 239000003576 central nervous system agent Substances 0.000 description 2
- 229940125693 central nervous system agent Drugs 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002792 enkephalinase inhibitor Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940125702 ophthalmic agent Drugs 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 229950000688 phenothiazine Drugs 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 2
- 239000000814 tuberculostatic agent Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 239000000775 AMPA receptor antagonist Chemical class 0.000 description 1
- 229940098747 AMPA receptor antagonist Drugs 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 229940124293 CD30 monoclonal antibody Drugs 0.000 description 1
- 229940124294 CD33 monoclonal antibody Drugs 0.000 description 1
- 229940124296 CD52 monoclonal antibody Drugs 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 108010049047 Echinocandins Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 1
- 206010058179 Hypertensive emergency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Chemical class 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229940124821 NNRTIs Drugs 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 101800001014 Non-structural protein 5A Proteins 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229940127355 PCSK9 Inhibitors Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 229940127315 Potassium Channel Openers Drugs 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 229940127524 Protease-activated Receptor-1 Antagonists Drugs 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100037346 Substance-P receptor Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229940124304 VEGF/VEGFR inhibitor Drugs 0.000 description 1
- 229940116211 Vasopressin antagonist Drugs 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229940126675 alternative medicines Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940124323 amoebicide Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 229940126905 angiotensin receptor-neprilysin inhibitor Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000000244 anti-pseudomonal effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 239000000059 antiamebic agent Substances 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940124286 antibiotics/antineoplastics Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000003409 antileprotic agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940124289 antineoplastic interferon Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003920 antivertigo agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 229940082649 blood substitutes and perfusion irrigating solutions Drugs 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940097228 centrally acting antiadrenergic agent Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 239000003467 chloride channel stimulating agent Substances 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940075527 detoxifying agent for antineoplastic treatment Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000001152 differential interference contrast microscopy Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940055061 drug used in alcohol dependence Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 229940041006 first-generation cephalosporins Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940041010 fourth-generation cephalosporins Drugs 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000028579 gamma-aminobutyric acid uptake involved in synaptic transmission Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000003933 gonadotropin antagonist Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000002607 heparin antagonist Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 229940124299 hormone/antineoplastic Drugs 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 229940124525 integrase strand transfer inhibitor Drugs 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 229940046732 interleukin inhibitors Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000013010 irrigating solution Substances 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000003835 ketolide antibiotic agent Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical class CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940116557 magnetic resonance imaging contrast media Drugs 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940047091 other immunostimulants in atc Drugs 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 229940125703 otic agent Drugs 0.000 description 1
- COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940079358 peripheral opioid receptor antagonist Drugs 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 229940097224 peripherally acting antiadrenergic agent Drugs 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 230000002215 photochemotherapeutic effect Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000002379 progesterone receptor modulator Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000003542 rubefacient Substances 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000003229 sclerosing agent Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940041008 second-generation cephalosporins Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 229940046729 selective immunosuppressants Drugs 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940094890 synthetic ovulation stimulants Drugs 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940127044 therapeutic radiopharmaceutical Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 150000005075 thioxanthenes Chemical class 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical class C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
- 229940125712 tocolytic agent Drugs 0.000 description 1
- 239000003675 tocolytic agent Substances 0.000 description 1
- 229940026754 topical antivirals Drugs 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960003853 ultrasound contrast media Drugs 0.000 description 1
- 208000030954 urea cycle disease Diseases 0.000 description 1
- 239000002432 uterotonic agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003038 vasopressin antagonist Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
- G01N29/04—Analysing solids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/02—Burettes; Pipettes
- B01L3/0241—Drop counters; Drop formers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
- G01N29/02—Analysing fluids
- G01N29/032—Analysing fluids by measuring attenuation of acoustic waves
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
- G01N29/04—Analysing solids
- G01N29/11—Analysing solids by measuring attenuation of acoustic waves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0626—Fluid handling related problems using levitated droplets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/14—Process control and prevention of errors
- B01L2200/143—Quality control, feedback systems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0433—Moving fluids with specific forces or mechanical means specific forces vibrational forces
- B01L2400/0439—Moving fluids with specific forces or mechanical means specific forces vibrational forces ultrasonic vibrations, vibrating piezo elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01G—WEIGHING
- G01G9/00—Methods of, or apparatus for, the determination of weight, not provided for in groups G01G1/00 - G01G7/00
-
- G01N2015/1021—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/023—Solids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/024—Mixtures
- G01N2291/02416—Solids in liquids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/024—Mixtures
- G01N2291/02458—Solids in solids, e.g. granules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/024—Mixtures
- G01N2291/02466—Biological material, e.g. blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/028—Material parameters
- G01N2291/02818—Density, viscosity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2291/00—Indexing codes associated with group G01N29/00
- G01N2291/02—Indexing codes associated with the analysed material
- G01N2291/028—Material parameters
- G01N2291/02854—Length, thickness
Definitions
- the invention relates to a method or process determining the weight, or other characteristics, especially of a material which is in the form of a solid particle or a liquid droplet, and to devices equipped for that purpose, as well as to related embodiments of the invention as disclosed in detail in the following.
- Standing acoustic waves can be relatively powerful, for example, they can cause dust to collect in a pattern corresponding to the wave's nodes. They can also be used for acoustic levitation, that is, for placing objects or materials in a hovering position without contact to any mechanical device or element. Increasing the power of the acoustic wave will increase the pressure in the standing nodes-eventually becoming high enough to balance the pull of gravity on objects placed in these nodes. Thus intensive sound is central to acoustic levitation --transducers in many levitators produce sounds in excess of 150 decibels (dB) .
- dB decibels
- the object or material being levitated should measure for example between one third and half of the wavelength of the sound.
- the sound wave must produce enough pressure to counteract the pull of gravity on the object or material in order to allow it to hover.
- the intensity of the sound must not overwhelm the surface tension of liquid droplets being levitated. If the sound field is too intense, the drop will flatten into a donut and then burst.
- US 6,109,098 describes methods and devices for determining the size of particles by sound attenuation and sound speed in liquid matrix.
- US 2012/0197005 A1 provides a method for producing a mixture of amorphous compounds, e.g. from crystalline materials, in an acoustic levitation field without liquid (in the gas phase) , comprising supplying a solution containing the compounds; and allowing at least a portion of the solvent of the solution to evaporate while preventing the solute of the solution from contacting a nucleation point.
- Some compounds are highly potent or toxic and require special containment environment when weighing or preparing samples or products to prevent contamination of operators.
- API active pharmaceutical ingredients
- These formulations are generally designed to enable mass manufacturing of the product by ensuring that a consistent dose of the API is in the product taken by the patient (for example /- 10 %of the label claim) and that the patient or care provider can handle the product.
- Excipients are added to make the formulation appropriate for processing (for example, API flows in the equipment to dispense a consistent dose in each capsule or tablet or other formulation option) or amenable to handling or compression e.g. into a tablet.
- Novel drug delivery systems for local delivery that require a matrix or formulation can be challenging to prepare and ensure a consistent dose. This is because the mixing with a matrix is challenging and needs to be processed extensively.
- Crystallization of solid from liquid and the subsequent characterization is routinely carried out in a separate manner.
- the disadvantages include: longer process procedures; storage; and sampling errors.
- radioactive materials where the use of contactless methods is especially useful, allowing to characterize and dispense material minimizing loss and radioactive contamination
- other materials used in trace amounts e.g. antibodies, active proteins, nucleic acids
- acoustic levitation provides a means to weigh materials, such as solid particles or liquid droplets, and to dispense them into appropriate containers or devices, making it possible to weigh and deliver exactly controlled amounts of such materials. Also other characterization is possible, as well as the dispensing of the material into desired destinations, e.g. (for example tableting, capsule, syringe or ampoule filling) devices or containers.
- Ultrasound levitation thus allows to separate particles e.g. of an active pharmaceutical compound from a bulk reservoir either as individual particles or a group of particles, move (dispense or transfer) these particles to the capsule or other formulation unit and deposit them there in a controlled manner, providing an accurate weight within known a known range or specification.
- This also allows the processing of crystals with morphology which have poor flow properties and that could normally not or only difficultly be used for drugs in a capsule or other dosage forms or formulations.
- the technology will also measure the weight of individual particles or a group of particles and is also appropriate to determine the number of particles of compound or carrier containing the compound.
- the invention describes a method of determining the weight of a material which is in the form of a solid particle or a liquid droplet, comprising introducing said material into an acoustic levitation field, so that it is positioned and kept in position by an acoustic node of a standing wave in the acoustic levitation field, determining the position of the material and using the position information to determine the weight of the material.
- the invention in a second aspect, relates to a method of dispensing a material in the form of a solid particle or a liquid droplet or mixture, comprising introducing said material into an acoustic levitation field, so that it is positioned and kept in position by an acoustic node of a standing wave in the acoustic levitation field, determining information on any one or more features selected from the position, the shape, the weight and the orientation of the material and using the obtained feature to dispense the material into a final destination.
- the invention describes an apparatus (device) appropriate or equipped for carrying out said method, comprising an acoustic transducer, an acoustic reflector, and a unit for determining the position of a material which is in the form of a solid particle or a liquid droplet.
- This apparatus is preferably (e.g. computer) programmed or can be (e.g. computer) programmed to allow to determine the position of the material to be weighed and to use the position information to determine the weight of said material.
- the method according to the first aspect of the invention in a first invention sub-aspect, especially is used for determining the weight where the material particle or droplet has a weight in the range from 0.1 ng to 5 g, e.g. from 0.1 ng to 100 mg, in particular from 1 ng to 5 or 1 mg.
- the method is used where the solid material is a result of liquid material comprising a solution or dispersion, including a suspension of a solid material in a solvent or solvent mixture or an emulsion of a liquid material in a solvent or solvent mixture that is not miscible with the solvent.
- the method according to the previous paragraph further comprises evaporating the solvent and forming the solid material in dry form.
- the dry form may, depending on the speed of evaporation, which may be supported by supplying energy, e.g. heat or microwave irradiation, may be amorphous, glassy, partially crystalline or completely crystalline (amixture of solid states) .
- the method in the preceding paragraphs is used where the material is solid and can be pulverous, crystalline, amorphous, a granule, a particle agglomerate, a mixture of solid states, a micelle material, a liposome material, a viral material, e.g. for vaccination purposes, cell component (e.g. membrane vesicles or mitochondria) or a cell material (meaning wherever mentioned a material including one or more cells, such as bacterial or fungal cells, e.g. for vaccination purposes, or e.g. cells from the immune system, such as lymphocytes or phagocytes) .
- cell component e.g. membrane vesicles or mitochondria
- a cell material meaning wherever mentioned a material including one or more cells, such as bacterial or fungal cells, e.g. for vaccination purposes, or e.g. cells from the immune system, such as lymphocytes or phagocytes
- the invention relates to the method according to any one of the preceding aspects (embodiments) wherein the material comprises a drug, a drug and excipient combination, an excipient, an intermediate for the synthesis of a drug, a cell component, a cellular material, a cell, or a plurality of cells.
- the material may be one useful in agriculture related chemistry, fine chemistry or other chemistry , a radioactive material or any other material used in small or trace amounts (e.g. antibodies, active proteins, nucleic acids) , where exact weighing and distribution of materials is desirable.
- the invention relates to the method according to any one of the preceding aspects, where the position is determined by an optical system, especially including a camera, or a laser detection system, e.g. a laser interferometer; a system for impedance measurement ; or by an acoustic system.
- an optical system especially including a camera, or a laser detection system, e.g. a laser interferometer; a system for impedance measurement ; or by an acoustic system.
- Yet another particular sub-aspect of the first aspect of the invention relates to the method according to any one of the preceding aspects, comprising further determining the shape of the material, especially where liquid droplet materials are used and more especially where solid materials are involved, e.g. in order to allow to determine the par-ticle or crystal shape and/or size in order to allow to conclude on processability e.g. du-ring the manufacture of a pharmaceutical or agrochemistry or cosmetic or chemistry or other formulation.
- Another sub-aspect of the first aspect of the invention refers to the method according to any one of the preceding aspects of the first aspect of the invention, comprising further determining the orientation of the particle or droplet.
- Another specific sub-aspect of the first aspect of the invention relates to the method according to the preceding paragraph wherein the orientation depends on the effect of the levitation field, acoustic node, or the material in the levitation field, or a combination of two or more of these parameters.
- Another sub-aspect of the first aspect of the invention also relates to the method according to any one of the preceding invention aspects, further comprising determining whether the material is in solid form or in liquid form or a combination or mixture thereof (e.g. a suspension or an emulsion or a micelular form) , as well as whether the material is crystalline or amorphous. Aggregates or combinations of the foregoing can also be determined.
- Another of the sub-aspects of the first aspect of the present invention relates to the method according to any one of the preceding aspects of the first aspect, wherein multiple particles or droplets are introduced into multiple nodes of (one and) the same standing wave simultaneously or sequentially and the determining of the weight of each takes place in parallel.
- An important sub-aspect of the first aspect of the invention relates to the method according to any one of the preceding aspects wherein the material is a drug, an excipient, a drug formulation, or intermediate, or placebo or inactive material.
- the method there may comprise determining the weight by a method according to any one of the preceding aspects of the invention.
- Another sub-aspect of the second aspect of the invention relates to the method according to any one of the second invention aspect and sub-aspects thereof wherein the further or final destination is selected based on information comprising one or more of the features selected from the position, the shape, the weight and/or the orientation of the material, especially one or more of a combination of these features including at least the weight.
- the method according to any one of the (sub-) aspects of the second aspect of the invention comprising dispensing more than one material particle or droplet to the same further or final destination and thus accumulating the material at that destination, especially comprising accumulating up to 10 g of material at the same destination, forms another sub-aspect.
- a further sub-aspect of the second invention relates to the method according to any one of the (sub-) aspects thereof mentioned so far, comprising using as the material a drug or drug formulation or placebo.
- Another sub-aspect of the second aspect of the invention relates to the method according to any one of its (sub-) aspects mentioned so far, wherein more than one material is used, that is two different material.
- the sub-aspect comprises two or more drugs, and/or in the case of a drug formulation two or more excipients with one or more drugs .
- Still another sub-aspect of the second aspect of the invention relates to the method according to any one of its (sub-) aspects mentioned so far, wherein the dispensing of the material is comprising shifting the position of said material so that it enters a device or container as further or final destination, especially comprising using a solid particle as material and shifting the position of the material so that it enters the device which is selected from a tableting and a capsule filling machine, more especially comprising shifting the position of the material into a container which is selected from a capsule, an ampoule, a syringe, a bottle, an infusion container, a sachet, a vial, a spray container or a blister pack, or food product (e.g. nutraceutical) container, each especially for pharmaceutical purposes, respectively.
- the dispensing of the material is comprising shifting the position of said material so that it enters a device or container as further or final destination, especially comprising using a solid particle as material and shifting the position of the material so that it enters the device
- a further sub-aspect of the second aspect of the invention relates to the method according to any one of its (sub-) aspects mentioned so far, comprising shifting the material to the destination by using multiple sound transducers, applying electrical fields, using gas (e.g. air) streams or blasts, moving the transducers of the levitating wave and/or superimposing a slow acoustic wave oriented in an angle different, for example greater than 0 ° relative to an axis of the levitating wave.
- a transporting wave may be arrayed at any angle form the vertical axis.
- shifting the material to the destination may be achieved by weakening or removing the acoustic levitation field, allowing the material to fall into a destination positioned below the material. Combinations of any of the foregoing may be employed.
- a further sub-aspect of the second aspect of the invention relates to the method according to any one of its (sub-) aspects mentioned so far, comprising affecting the material using mechanical means to transport it into the device or container.
- the method according to any one of the sub-aspects of the second aspect of the invention comprising using mechanical means to move the receiving device and con-tainer under the material and subsequently disabling the acoustic field to capture the particle in the device, forms an invention sub-aspect.
- Yet another sub-embodiment (sub-aspect) of the second aspect of the invention relates to a method according to any one of the aspects or sub-aspects of the second invention mentioned so far, comprising determining the vertical position of the material in order to determine the weight of the material. This is especially important as it allows for precise delivery of amounts of material to containers or ampoules, which may be determined with standard deviations of 1 %or less and are thus much more precisely determined and distributed than in other weigh determination methods.
- Another sub-aspect of the second aspect of the invention relates to the method according to any one of its preceding (Sub-) aspects, wherein the position of the material is determined by an optical system or a sound system; especially wherein the position and if part of the respective claim any other feature mentioned is determined with a high-speed microscopic system.
- a further sub-aspect of the second aspect of the invention relates to the method according to any one of its preceding (sub-) aspects, comprising providing units of the material (s) with an electric charge of identical polarity in order to inhibit its or their aggre-gation or to allow to move (dispense) them by means of electric field (s) ; or with an electric charge of different polarity in order to promote its or their aggregation or to allow to move (dispense) them by means of electric field (s) .
- the method according to any one of the preceding (sub-) aspects of the second invention may comprise controlling one or more parameters selected from the groups consisting of the temperature, charge, humidity, pressure, and operating conditions of the device housing the material (and/or levitation field) .
- the method according to any one of the preceding (sub-) aspects of the second aspect of the invention may comprise determining the weight by calibration with particles or droplets of known weight, e.g. by way of a calibration curve (which may be implemented in programmed form) .
- the present invention also, in a third aspect, relates to a device or apparatus appropriate, especially adapted or equipped, e.g. programmed and comprising the means, for executing a method according to any of the invention aspects and sub-aspects defined so far.
- the invention thus relates to an apparatus (device) comprising an acoustic transducer, an acoustic reflector, and a unit for determining the position of a material which is in the form of a solid particle or a liquid droplet.
- This apparatus as said unit for determining the position of the material, preferably is an optical system, especially comprising a microscope and a high-speed imaging device.
- the apparatus comprises an input element for the material.
- Such input element may, for example, be a container with the material (which may already be in particle or droplet form, e.g. in the form of a fluid bed (maintained by gas and/or ultrasound) or spouted bed) , a microfluidic element allowing to feed droplets of material, a micro cup, a funnel or the like.
- the apparatus further preferably comprises a unit or element for shifting the position of the material in an acoustic node.
- the apparatus may, in a further invention embodiment, comprise a unit to collect material positioned, characterized and/or weighed in an acoustic node.
- This unit may be a device or a container.
- Particle in particular means a (under the temperature conditions during application of a method or device according to the invention) solid material that may be a monolithic particle or an aggregate of solid material sub-particles, e.g. a granulate or agglomerate.
- Droplet in particular means a material with a (under the temperature conditions during application of a method or device according to the invention) liquid continuous matrix which is the sole phase present, or they may comprise solid material (including micelles or liposomes) as non-continuous phase, e.g. as a suspension, or immiscible liquid material, e.g. sub-droplets, e.g. in a water-in-oil or oil-in-water emulsion. Droplets may be disrupted into sub-droplets or they may be united to form larger droplets in the acoustic field or when dispensed into a container or device.
- a “micelle” material is especially one comprising supermolecular colloid particles, often including a packet of chain molecules in parallel arrangement, e.g. formed from surface active (amphiphilic) substances.
- a “liposome material” is especially a material comprising spherical vesicles having at least one lipid bilayer.
- a “viral material” may e.g. be formed from proteins and/or nucleic acids which at least partially correspond to proteins and/or nucleic acids in virus, or genetically modified variants thereof, or complete virus (which may be inactivated e.g. for vaccination purposes) .
- a “cell component” may e.g. comprise membrane vesicles from organelle or the outer membrane of cells, or complete organelles, such as mitochondria.
- cell material preferably a material comprising one or more cells, such as bacterial or fungal cells, e.g. for vaccination purposes, or e.g. cells from the immune system, such as lymphocytes or phagocytes, e.g. cells allowing to provide monoclonal antibodies, can be meant.
- cells such as bacterial or fungal cells, e.g. for vaccination purposes, or e.g. cells from the immune system, such as lymphocytes or phagocytes, e.g. cells allowing to provide monoclonal antibodies.
- optical system may comprise a camera, a laser detection system or a high speed (especially microscopic) system.
- a “camera” is an optical instrument allowing to record images (single images or sequences of images, e.g. in the form of videos or movies) which may be stored, transmitted to another location, or both.
- a digital camera is one preferred embodiment. The camera may work with the light of the visible spectrum or with other portions of the electromagnetic spectrum, e.g. UV light.
- a “laser detection system” is any laser system that allows to determine distances or positions of materials, or any other properties thereof, such as its surface properties, refractive index, density or the like. Examples are laser measuring devices or laser interferometers. Such systems e.g. allow for the testing of the kind of surface of a solid or liquid material according to the invention embodiments and make it possible to achieve high precision examination of surface topography. Exact imaging is possible e.g. by optical coherence tomography, phase contrast and differential interference contrast microscopy, angle-resolved low-coherence interferometry or phase-contrast X-ray imaging. Laser detection systems can also be used to determine indices of refraction and thermal properties.
- a high-speed (especially microscopic) system including or as part of a camera, may be an especially useful device to determine the position of the material.
- weight of a particle is determined by determining the vertical position (e.g., location of the particle relative to a lower sound transducer surface or any other reference height or datum) , and comparing the determined location to a calibration plot in order to determine the weight of the particle.
- a device or container as final destination may comprise a device that allows for the distribution into a unit form of a pharmaceutical preparation, e.g. a container as mentioned in the following, and may e.g. be an ampoule filling, capsule filling or tablet forming device; a container may e.g. be selected from a capsule, an ampoule, a syringe, a bottle, an infusion container, a sachet, a vial and a blister pack.
- a device or container as further destination may comprise a device or container that is useful or necessary for some further processing, distribution or handling of the material as an intermediate prior to achieving the final unit form of a pharmaceutical preparation, and may e.g. comprise a filling, transporting, or conditioning device; a con-tainer may e.g. be selected from a well, capsule, ampoule, syringe, bottle, infusion container, sachet, vial and blister.
- the shifting the material to the destination by using multiple sound transducers may make use of superimposition of acoustic waves or a tuning of the waves so that to-gether, at least during the dispensing of a material in liquid droplet or solid particle form, sound waves are influenced and added so as to provide a force that drives the material to or above the desired position.
- This effect may also be obtained by moving the transducers of the levitating wave to a position where the material is to be dispensed to.
- superimposing a slow acoustic wave oriented in an angle different from 0° relative to an axis of the levitating wave may allow for such shift in the position of the material.
- the particles may also be moved by applying electrical fields, e.g. using two or more electrodes of appropriate charge.
- a material particle or droplet may experience a force allowing it to be dispensed at or moved to a desired destination.
- gas e.g. air
- the dispensing method may (in addition or in combination with any one or more of the other methods appropriate, e.g. as just mentioned) comprise shifting the material to the destination by weakening or removing the acoustic levitation field, allowing the material to fall into a desired destination positioned below the material.
- mechanical means may be used to move the material hovering in the levitation field to a desired destination.
- These mechanical means may include directly inserting the destination device or container in the field which may lead to a disruption that allows the hovering material to be supplied to the destination.
- the mechanical means may be robot arms (e.g. equipped with forceps) , plungers, e.g. in rod shape, threads, wires, filaments, sheet-like materials or the like.
- the mechanical means may also be a ratchet or conveyor belt, bar or roller that allows to position containers or devices, e.g. vials or ampoules or open capsules or the like, below a position allowing to deliver the material to them, e.g. to a position below the lower confinement of the room in which acoustic levitation is effected, for example through a hole in said lower confinement.
- containers or devices e.g. vials or ampoules or open capsules or the like
- the dispensing takes place without need for the material to come into contact with a surface other than that in or at the destination, thus allowing to decrease risks of contamination or material loss on such surfaces.
- the material treated or manipulated according to the invention may be supplied with an electric charge of identical polarity in order to inhibit its or their aggregation; or with an electric charge of different polarity in order to promote its or their aggregation.
- This allows to (e.g. also by moving the material portions towards or away from each other) to form larger particle aggregates or larger droplets.
- droplets it is possible to explode them (e.g. by administration of sufficiently strong sound waves) into smaller droplets and thus to yield smaller material droplets.
- dispense or “dispensing” of a material especially relates to its transfer and deposition at a desired destination.
- the material can be delivered in a precise amount or with precise knowledge to a desired destination, even without contacting it with any surfaces other than those at the destination.
- the term “food product” comprises, for example, a “nutraceutical” (sometimes also called “Functional Food” , “Functional Food product” , “Foodsceutical” , “Medicinal Food” or “Designer Food” ) and, according to the present invention embodiments, is defined as food product (including beverages) suitable for human consumption–the expression comprises any fresh or processed food having a health-promoting and/or disease-preventing property beyond the basic nutritional function of supplying nutrients, including food made from functional food ingredients or fortified with health-promoting additives, especially with an effects in the prophylaxis or treatment of one or more of the disorders mentioned herein, in which a material obtained (especially dispensed) according to the invention is added as an ingredient (especially as additive) as health benefit agent, especially in an effective amount, as well as any partially or totally artificially composed food.
- a material obtained (especially dispensed) according to the invention is added as an ingredient (especially as additive) as health benefit agent, especially in an effective amount, as well as any partially
- the nutraceuticals can alternatively be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions, suspensions, parenteral products (e.g. intra venous infusions or injects or subcutaneous injects) or the like.
- composition comprises any type of formulation known in the art.
- Said formulation may comprise one or more drugs ( “active ingredients” ) with or without (pharmaceutically acceptable) excipient (s) .
- Drugs may be selected from antibodies, vaccines, enzymes or small molecule organic drugs or other therapeutically active molecules.
- the active ingredient (s) may, for example, be selected from the (non-limiting) group consisting of 5-alpha-reductase inhibitors, 5-aminosalicylates, 5HT3 receptor antagonists, AACE inhibitors with calcium channel blocking agents, ACE inhibitors with thiazides, adamantane antivirals, adrenal cortical steroids, adrenal corticosteroid inhibitors, adrenergic bronchodilators, agents for hypertensive emergencies, agents for pulmonary hypertension, aldosterone receptor antagonists, alkylating agents, allergenics, alpha-glucosidase inhibitors, alternative medicines, amebicides, aminoglycosides, aminopenicillins, aminosalicylates, AMPA receptor antagonists, amylin analogs, analgesic combinations, analgesics, androgens and anabolic steroids, angiotensin converting enzyme inhibitors, angiotensin II inhibitors with calcium channel blockers, angiotensin II inhibitors alone
- antiadrenergic agents peripherally acting antiadrenergic agents
- peripherally acting antiandrogens antianginal agents, antiarrhythmic agents, antiasthmatic combinations
- antibiotics/antineoplastics anticholinergics, antiemetics, anticholinergic antiparkinson agents, anticholinergic bronchodilators, anticholinergic chronotropic agents, anticholinergics/antispasmodics, anticoagulants, anticonvulsants, antidepressants, antidiabetic agents, antidiabetic combinations, antidiarrheals, antidiuretic hormones, antidotes, antiemetic/antivertigo agents, antifungals, antigonadotropic agents, antigout agents, antihistamines, antihyperlipidemic agents, antihyperlipidemic combinations, antihypertensive combinations, antihyperuricemic agents
- pylori eradication agents H2 antagonists, hedgehog pathway inhibitors, hematopoietic stem cell mobilizer, heparin antagonists, heparins, HER2 inhibitors, herbal products, histone deacetylase inhibitors, hormones, hormones/antineoplastics, hydantoin anticonvulsants, hydrazide derivatives, illicit (street) drugs, immune globulins, immunologic agents, im-munostimulants, immunosuppressive agents, impotence agents, in vivo diagnostic bio- logicals, incretin mimetics, inhaled anti-infectives, inhaled corticosteroids, inotropic agents, insulininsulin-like growth factor, integrase strand transfer inhibitor, interferons, interleukin inhibitors, interleukins, intravenous nutritional products, iodinated contrast media, ionic iodinated contrast media, iron products, ketolides, laxatives, leprostatics, eukot
- the present invention relates also to pharmaceutical formulations (pharmaceutical compositions) that comprise an active ingredient as or included in a material obtained (e.g. dispensed) according to the invention and that can be used especially in the treatment of the diseases mentioned herein.
- the material of the present invention may be used, for example, for the preparation of pharmaceutical compositions that comprise a pharmaceutically effective amount of a material.
- the active ingredient in said material may be present in free form or in the form of a pharmaceutically acceptable salt, solvate, hydrate or polymorph, or in admixture with a significant amount of one or more inorganic or organic, solid or liquid, pharmaceutically acceptable excipients (carriers) .
- compositions for enteral administration such as nasal, buccal, rectal or, especially, oral administration
- parenteral administration such as intravenous, intramuscular or subcutaneous administration, to warm-blooded animals, especially humans
- the compositions comprise the active ingredient alone or, preferably, together with a pharmaceutically acceptable excipient (carrier) .
- carrier a pharmaceutically acceptable excipient
- the dosage of the active ingredient depends upon the disease to be treated and upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, and the mode of administration.
- the pharmaceutical compositions comprise from approximately 0.0001%to approximately 100% (%referring to weight percent) active ingredient, single-dose administration forms comprising in the preferred embodiment from approximately 0.001%to approximately 100%active ingredient and forms that are not of single-dose type comprising in the preferred embodiment from approximately 5%to approximately 20%active ingredient.
- Unit dose forms are, for example, coated and uncoated tablets, ampoules, vials, suppositories, sachets, sprinkles, spray containers or capsules.
- Further dosage forms are, for example, ointments, creams, pastes, foams, tinctures, sprays, etc. Examples are capsules or tablets or ampoules containing from about 0.0001 mg to about 1.0 g, e.g. from 0.001 to 5 mg material dispensed according to the invention embodiments.
- compositions of the present invention are, taking reference to the inventive dispensing, otherwise prepared in a manner known per se, for example by means of conventional mixing, granulating, coating, dissolving or lyophilizing processes or by mixing using a method or device according to the invention.
- compositions of the material with the active ingredient Preference is given to the use of solutions of the material with the active ingredient, and also suspensions or dispersions, especially isotonic aqueous solutions, dispersions or suspensions which, for example in the case of lyophilized compositions comprising the active ingredient alone or together with a carrier can be made up before use.
- the pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes.
- the said solutions or suspensions may comprise viscosity-increasing agents or solubilizers, such as sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone or gelatin.
- Suspensions in oil comprise as the oil component the vegetable, synthetic or semi-synthetic oils customary for injection purposes.
- liquid fatty acid esters that contain as the acid component a long-chained fatty acid having from 8 to 22, especially from 12 to 22, carbon atoms, for example lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brasidic acid or linoleic acid, if desired with the addition of anti-oxidants, for example vitamin E, ⁇ -carotene or 3, 5-di-tert-butyl-4-hydroxytoluene.
- anti-oxidants for example vitamin E, ⁇ -carotene or 3, 5-di-tert-butyl-4-hydroxytoluene.
- the alcohol component of those fatty acid esters has a maximum of 6 carbon atoms and is a mono-or poly-hydroxy, for example a mono-, di-or tri-hydroxy, alcohol, for example methanol, ethanol, propanol, butanol or pentanol or the isomers thereof, but especially glycol and glycerol.
- fatty acid esters are therefore to be men-tioned: ethyl oleate, isopropyl myristate, isopropyl palmitate, "Labrafil M 2375” (polyoxy-ethylene glycerol trioleate, Gattefossé, Paris) , "Miglyol 812” (triglyceride of saturated fatty acids with a chain length of C 8 to C 12 , Hüls AG, Germany) , but especially vegetable oils, such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.
- vegetable oils such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.
- Injection compositions are prepared in customary manner under sterile conditions; the same applies also to introducing the compositions into ampoules or vials and sealing the containers.
- compositions for oral administration which are also especially preferred can be obtained by combining the material with the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture, if desired or necessary, after the addition of appropriate excipients, into tablets, dragée cores or capsules. It is also possible for them to be incorporated into plastics carriers that allow the active ingredients to diffuse or be released in measured amounts.
- Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and binders, such as starch pastes using for example corn, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, and/or carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate.
- fillers such as sugars, for example lactose, saccharose, mannitol or sorbitol
- cellulose preparations and/or calcium phosphates for example tricalcium phosphate or calcium hydrogen phosphate
- Excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol.
- Dragée cores are provided with suitable, optionally enteric, coatings, there being used, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as ethylcellulose phthalate or hydroxypropylmethylcellulose phtha-late.
- Capsules are dry-filled capsules made of gelatin or HPMC and soft sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the dry-filled capsules may comprise the active ingredient in the form of granules, for example with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and if desired with stabilizers.
- the active ingredient is preferably dissolved or suspended in suitable oily excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilizers and/or antibacterial agents to be added.
- suitable oily excipients such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilizers and/or antibacterial agents to be added.
- Dyes or pigments may be added to the tablets or dragée coatings or the capsule casings, for example for identification purposes or to indicate
- Tablet cores can be provided with suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations.
- suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations.
- compositions suitable for rectal administration are, for example, suppositories that consist of a combination of the active ingredient and a suppository base.
- aqueous solutions of an active ingredient in water-soluble form for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers, are especially suitable.
- the active ingredient optionally together with excipients, can also be in the form of a lyophilizate and can be made into a solution before parenteral administration by the addition of suitable solvents.
- Solutions such as are used, for example, for parenteral administration can also be employed as infusion solutions.
- the term “excipient” especially refers to any pharmaceutically or nutraceutically acceptable carrier material as already mentioned and also and includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents) , isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combi-nations thereof, as would be known to those skilled in the art. Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
- a therapeutically effective amount especially refers to an amount of the material obtainable according to the present invention (especially the active ingredient forming it or comprised in it) that will elicit the biological or medical response of a subject suffering from a disease or disease symptoms, including ameliorating the status of a subject suffering from said disease, alleviating the disease or one or more of its symptoms, or preventing the disease, or the like.
- the term “subject” refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female) , cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is in particular a human.
- a daily dosage (which may be split up into two or more, e.g. up to three dosage units) may be in the range from 0.0001 mg to 5000 mg, such as from 0.001 to 5 mg, e.g. from 0.001 to 1 mg.
- Placebo formulations may comprise solely the excipient material (s) and may be useful in the placebo treatment or in clinical trials.
- Diseases may, for example, be selected from the group consisting of infectious and parasitic diseases, especially lower respiratory tract infections, diarrhea, AIDS, tuberculosis, and malaria; neuropsychiatric conditions, e.g. depression; injuries, especially motor vehicle accidents, cardiovascular diseases, principally heart attacks and stroke, premature birth and other perinatal deaths, gastrointestinal disorders, and cancer. Any disease or disorder encompassed by these general terms or any other disease or disorder may be comprised.
- intermediate relates to any compound which is used as starting material or intermediate in the synthesis of a final drug molecule.
- examples are organic low molecular weight compounds, enzymes, antibodies or specifically binding parts thereof, nucleic acids or nucleic acid derivatives, such as siRNA, or the like, especially selected from the active ingredients mentioned above.
- the present invention also comprises the following embodiments which can be claimed:
- a pharmaceutical or neutraceutical composition comprising a material obtained (es-pecially dispensed) according to a method of the invention as active ingredient together with a pharmaceutically acceptable diluent or carrier, especially for use in the therapeutic and/or prophylactic treatment of a disease or disorder, e.g. mentioned herein.
- a method for the treatment of a disorder comprising administering a pharma-ceutically effective amount of a material obtained (especially dispensed) according to a method of the invention, especially to an individual in need thereof.
- a method as defined above comprising co-administration, e.g. concomitantly or in sequence, a therapeutically effective amount of a material obtained (especially dispensed) according to a method of the invention, and a different pharmaceutically active compound and/or a pharmaceutically acceptable salt thereof, said different pharmaceutically active compound and/or salt thereof being especially for use in the treatment of any one or more of the disorders set forth hereinbefore or hereinafter.
- a combination product comprising a therapeutically effective amount of a material obtained (especially dispensed) according to a method of the invention, and a different pharmaceutically active compound and/or a pharmaceutically acceptable salt thereof, said second pharmaceutically active compound being especially for use or of use in the treatment of any one or more of the particular disorders set forth hereinbefore.
- Fig. 1 shows a schematic representation of an embodiment of acoustic levitation of a particle.
- Fig. 2 is a graph showing the distribution of sound pressure level (in dB) and the vertical position in an embodiment of an acoustic levitation field relative to the distance from a node 4 in mm.
- Fig. 3 is a calibration curve for an embodiment of the invention for a determination of weight of a particle and its vertical position in an acoustic levitation field relative to the position with maximum sound pressure (the “datum” ) .
- Fig. 4 schematically represents an apparatus according to an embodiment of the invention that allows for the touch-free transport (dispensing) of a material to a desired destination, here capsule halves.
- Fig. 5 schematically illustrates, in an embodiment of the invention, how material levitation is detected and converted to weight measurement.
- FIG. 1 the principle of acoustic levitation, according to various embodiments of the invention, is represented.
- a transducer 1 and a reflector 2 are set up in a distance that allows an acoustic standing wave to be formed between them.
- a material 3 here in a non-limiting way a particle
- a node 4 capture node, positive sound pressure area
- the corresponding sound velocity wave 6 and the sound pressure wave 7 are represented schematically.
- the material 3 is kept in the upper area of the node 4 as there, the lower the position, the higher the pressure to keep it in its hovering position is. If the particle is (e.g. by shift of the position of the node or by decreasing the energy of the sound wave) reaching the lower half of the node 4, it may drop through this lower part (with declining pressure) and the antinode 5 and then be held by the next node 4 in a hovering position or drop e.g. through a hole in the transducer to a desired destination. This allows for one way to deliver a material without touching (and thus e.g. contaminating or otherwise influencing the surface of it) it to a desired destination.
- the particle e.g. by shift of the position of the node or by decreasing the energy of the sound wave
- Fig. 2 shows an example for the measured sound level for an actually established standing acoustic wave (the sound pressure level profile in the particle levitator for one set of operating conditions actually used) .
- Node 4 and antinode 5 of the actual sound pressure wave 7 and their height relative to the datum (amaximum sound pressure position, i.e. a node) are shown.
- the sound pressure level can, for example, be determined with a sound pressure calibration sensor 15) as shown in Fig. 4.
- Fig. 3 the result of levitation height and corresponding weight determination of particles are shown.
- the particles levitate at different heights depending on their size and hence weight.
- the sound pressure level In an ideal case we would expect the sound pressure level to be perfectly sinusoidal.
- a calibration curve represented in Fig. 3 was established by actually determining the position relative to a datum (apredetermined location–in this case the surface of the transducer) for a range of particles with known weights and generating a calibration plot.
- Fig. 3 In order to perform a calibration, in the example represented in Fig. 3 several different particle diameters were levitated within the acoustic particle levitator at the same time.
- the nominal particle diameters used were 20 microns ( ⁇ m) , 50 ⁇ m and 100 ⁇ m.
- the sizes of all three particle species are known to within 1%because they are calibration standard particles and hence can be treated as particles of known weight and density. (These particles are NIST-standard particles and exact diameters and density–and hence weight -are provided by the manufacturer) . These particle diameters were chosen to span the particle size range that the experimentators were interested in and do not represent the maximum or minimum particle diameters that can be levitated.
- the larger (heavier) particle has a lower position in the same node than the smaller (less heavy) particle (not shown) .
- Fig. 4 shows an example for an apparatus according to the invention that allows to both measure the material portion, e.g. particle, weight and to dispense the material to a devi-ce or container, here to capsule halves 22 on an output device 21, here in the exemplary form of a conveyor or collection device.
- the standing wave is produced by sound transducers 1, (here illustrated as an upper and lower transducer, but alternatively one of which may also be a sound reflector 2.
- the material e.g. a particle or droplet of a drug material, such as an ibuprofen particle
- a material supply 8 here represented as an arrow
- the acoustic trap sites 11 correspond to nodes 4 in Fig. 1 and Fig. 2.
- the particles may be delivered to specific trap sites 11.
- Arrow 12 represents the direction of particle flow in the Fig.
- An optional optical system may be positioned near particle introduction and allows to control the particle entry if desired.
- An additional or alternative optional optical system may be positioned below a particle outdrop tube 19
- the optical system 14 (e.g. a camera) allows to determine the position of a material portion (e.g. particle) at node 4 and thus provides the information required to determine its weight (e.g. from a calibration curve as shown in Fig. 3 which can be programmed into a computer 25 as shown in Fig. 5, for example) .
- a sound pressure level calibrations sensor 15 may be provided e.g, in order to allow for calibration based on sound pressure and/or to control the sound pressure if for example by lowering the sound intensity (energy) or by switching it off the particle (s) are to be dispensed to a desired destination, such as the capsule halves 22 shown here paradigmatically.
- This may be controlled by a detection unit (not shown) or the particle may simply fall through, e.g., outdrop tube 19 through which the material portion, e.g. particle, may fall without contacting it.
- the output may be controlled by an optional optical system (not shown) which may interface with a detection unit 18.
- Defective material e.g. of undesired shape, weight or density
- may for example by use of a sound wave used in perpendicular direction to the wave represented by the trap sites 11 in the Figure) dispensed (transferred) to a collection vessel 17 under the control of the detection unit (e.g. extraction tube) 18 for defective material.
- the detection unit e.g. extraction tube
- the dispensing of material portions may take place laterally (horizontally, e.g. perpendicular to the vertical wave axis) to a position other than outdrop tube 19, e.g. by electrical fields (then the material portions are preferably provided in a charged form) or superimposed sound wave allowing to shift the particles laterally (which can also be done as depicted here for defective particles only) .
- Fig. 5 shows another schematic representation of a device forming an invention embodiment for weighing a material particle 3, also schematically depicting the sound pressure wave 7 and showing the particle position relative to a datum 24 which is the po-sition of maximum sound pressure in the corresponding node.
- a camera is shown as an example of an optical system 14, and allows for the position determination of the material particle 3, here represented as levitation height X above the datum 24, and computer 25 allows for determining the weight of the particle 3 and for controlling the device.
Abstract
A method of determining the weight of a material (3) which is in the form of a solid particle or a liquid droplet, comprising introducing said material (3) into an acoustic levitation field, so that it is positioned and kept in position by an acoustic node (4) of a standing wave in the acoustic levitation field, determining the position of the material (3) and using the position information to determine the weight of the material (3); to a method of dispensing a material (3) in the form of a solid particle or a liquid droplet or mixture, comprising introducing said material (3) into an acoustic levitation field, so that it is positioned and kept in position by an acoustic node (4) of a standing wave in the acoustic levitation field, determining information on any one or more features selected from the position, the shape, the weight and the orientation of the material (3) and using the obtained feature to dispense the material (3) into a final destination; and to apparatus for use in the methods mentioned.
Description
Summary ofthe Invention
The invention relates to a method or process determining the weight, or other characteristics, especially of a material which is in the form of a solid particle or a liquid droplet, and to devices equipped for that purpose, as well as to related embodiments of the invention as disclosed in detail in the following.
Standing acoustic waves can be relatively powerful, for example, they can cause dust to collect in a pattern corresponding to the wave's nodes. They can also be used for acoustic levitation, that is, for placing objects or materials in a hovering position without contact to any mechanical device or element. Increasing the power of the acoustic wave will increase the pressure in the standing nodes-eventually becoming high enough to balance the pull of gravity on objects placed in these nodes. Thus intensive sound is central to acoustic levitation --transducers in many levitators produce sounds in excess of 150 decibels (dB) .
It is important to tune the correct frequency to match the distances between the transducer or transducers or the reflecting elements and/or vice versa in order to create the desired standing wave with stable nodes and antinodes. Most systems use ultrasonic waves, which are too high-pitched for people to hear. In addition to the frequency and volume of the wave, researchers also must pay attention to a number of other factors:
The object or material being levitated should measure for example between one third and half of the wavelength of the sound. The sound wave must produce enough pressure to counteract the pull of gravity on the object or material in order to allow it to hover. The intensity of the sound must not overwhelm the surface tension of liquid droplets being levitated. If the sound field is too intense, the drop will flatten into a donut and then burst.
US 6,109,098 describes methods and devices for determining the size of particles by sound attenuation and sound speed in liquid matrix.
US 2012/0197005 A1 provides a method for producing a mixture of amorphous compounds, e.g. from crystalline materials, in an acoustic levitation field without liquid (in the gas phase) , comprising supplying a solution containing the compounds; and allowing at least a portion of the solvent of the solution to evaporate while preventing the solute of the solution from contacting a nucleation point.
Companies often have substantial libraries of compounds or substances in libraries that require dispensing prior to testing or preparation. For example pharmaceutical companies will have libraries that may contain up to a million compounds. The most desirable way to store these compounds is as a solid because it reduces the risk of stability issues or precipitation from solutions due to freeze/thawing. Weighing samples manually is often required if the compounds are solids and there are often errors or challenges in dispensing small quantities of highly variable materials with different morphologies (i.e. crystal shapes or amorphous materials or oils, etc) . Furthermore only very small quantities may be required to be dispensed (<1 mg) and this is challenging to do accurately or without considerable loss of material or considerable time.
Some compounds are highly potent or toxic and require special containment environment when weighing or preparing samples or products to prevent contamination of operators.
Currently pharmacy (hospital and retail) provide patients with formulations of active pharmaceutical ingredients (API) . This requires substantial storage area for the products and for pharmaceutical companies to spend considerable time and effort to develop formulations containing the API and excipients in a form that can be handled by patients in packaging. These formulations are generally designed to enable mass manufacturing of the product by ensuring that a consistent dose of the API is in the product taken by the patient (for example /-10 %of the label claim) and that the patient or care provider can handle the product. Excipients are added to make the formulation appropriate for processing (for example, API flows in the equipment to dispense a
consistent dose in each capsule or tablet or other formulation option) or amenable to handling or compression e.g. into a tablet.
There are often issues with homogeneity of the product or stability of the product with excipients or issues with packaging. Furthermore, customarily 2 years of shelf life have to be generated on each product so that the product is stable during shipment, storage at the pharmacy and during period with the patient. In addition many patients are on multiple treatments and combination of API’s. This makes it difficult for patients to be compliant.
Currently pharmaceutical companies will develop a product for the average patient and one or two or three dosage forms to manage size or gender or age differences.
Genetic and biomarker technology is generating a need for products that enable a specific dose and regime for a specific individual which is not easily met by the con-vention formulation approach presently.
This is currently performed manually and is the most labor intensive stage of most laboratory operations. It is also the largest source of errors resulting in subsequent experiments. The issue is that materials are different and cause issues such as electrostatic repulsion or attraction, sticking together or to surfaces, or are oily or gluing or are inconsistent in texture. Furthermore it is difficult to measure accurately amounts of 5 or less mg, especially< 1 mg, and consequently much material is wasted due to higher than required amounts being used to ensure an accurate weighing. To achieve desired low concentrations it is often required that the compound is dissolved in a solvent and diluted to the desired concentration. This may also lead considerable errors and require the repetition of experiments.
Novel drug delivery systems for local delivery that require a matrix or formulation can be challenging to prepare and ensure a consistent dose. This is because the mixing with a matrix is challenging and needs to be processed extensively.
Most processes used to crystallize a product generate material that is inconsistent with respect to size and morphology. This often means that milling or further processing is required leading to loss of material or time required to process material further. Chemical impurity or solid state polymorphs occurs during manufacturing.
Crystallization of solid from liquid and the subsequent characterization is routinely carried out in a separate manner. The disadvantages include: longer process procedures; storage; and sampling errors.
Also in other fields (e.g. agriculture related chemistry, chemistry and fine chemistry, also fields implying radioactive materials (where the use of contactless methods is especially useful, allowing to characterize and dispense material minimizing loss and radioactive contamination) or other materials used in trace amounts (e.g. antibodies, active proteins, nucleic acids) , exact weighing and distribution of materials is desirable.
In view of these issues and limitations of drug or other material handling and dispensing, it is desirable to provide a method and devices allowing to determine exact amounts of materials and to allow to dispense them for example in containers or devices e.g. for the preparation of dosage forms without having to touch them by any mechanical means during weighing and dispensing.
General Description of the Invention
It has now been found that acoustic levitation provides a means to weigh materials, such as solid particles or liquid droplets, and to dispense them into appropriate containers or devices, making it possible to weigh and deliver exactly controlled amounts of such materials. Also other characterization is possible, as well as the dispensing of the material into desired destinations, e.g. (for example tableting, capsule, syringe or ampoule filling) devices or containers.
Ultrasound levitation thus allows to separate particles e.g. of an active pharmaceutical compound from a bulk reservoir either as individual particles or a group of particles, move (dispense or transfer) these particles to the capsule or other
formulation unit and deposit them there in a controlled manner, providing an accurate weight within known a known range or specification. This also allows the processing of crystals with morphology which have poor flow properties and that could normally not or only difficultly be used for drugs in a capsule or other dosage forms or formulations. The technology will also measure the weight of individual particles or a group of particles and is also appropriate to determine the number of particles of compound or carrier containing the compound.
In a first aspect, the invention describes a method of determining the weight of a material which is in the form of a solid particle or a liquid droplet, comprising introducing said material into an acoustic levitation field, so that it is positioned and kept in position by an acoustic node of a standing wave in the acoustic levitation field, determining the position of the material and using the position information to determine the weight of the material.
In a second aspect, the invention relates to a method of dispensing a material in the form of a solid particle or a liquid droplet or mixture, comprising introducing said material into an acoustic levitation field, so that it is positioned and kept in position by an acoustic node of a standing wave in the acoustic levitation field, determining information on any one or more features selected from the position, the shape, the weight and the orientation of the material and using the obtained feature to dispense the material into a final destination.
In a third aspect, the invention describes an apparatus (device) appropriate or equipped for carrying out said method, comprising an acoustic transducer, an acoustic reflector, and a unit for determining the position of a material which is in the form of a solid particle or a liquid droplet. This apparatus is preferably (e.g. computer) programmed or can be (e.g. computer) programmed to allow to determine the position of the material to be weighed and to use the position information to determine the weight of said material.
The method according to the first aspect of the invention, in a first invention sub-aspect, especially is used for determining the weight where the material particle or droplet has a weight in the range from 0.1 ng to 5 g, e.g. from 0.1 ng to 100 mg, in particular from 1 ng to 5 or 1 mg.
In one sub-aspect of the first aspect of the invention, the method is used where the solid material is a result of liquid material comprising a solution or dispersion, including a suspension of a solid material in a solvent or solvent mixture or an emulsion of a liquid material in a solvent or solvent mixture that is not miscible with the solvent.
In a further sub-aspect of the first aspect of the invention, the method according to the previous paragraph further comprises evaporating the solvent and forming the solid material in dry form. The dry form may, depending on the speed of evaporation, which may be supported by supplying energy, e.g. heat or microwave irradiation, may be amorphous, glassy, partially crystalline or completely crystalline (amixture of solid states) .
In yet a further sub-aspect of the first aspect of the invention, the method in the preceding paragraphs is used where the material is solid and can be pulverous, crystalline, amorphous, a granule, a particle agglomerate, a mixture of solid states, a micelle material, a liposome material, a viral material, e.g. for vaccination purposes, cell component (e.g. membrane vesicles or mitochondria) or a cell material (meaning wherever mentioned a material including one or more cells, such as bacterial or fungal cells, e.g. for vaccination purposes, or e.g. cells from the immune system, such as lymphocytes or phagocytes) .
In another sub-aspect of the first aspect of the invention, the invention relates to the method according to any one of the preceding aspects (embodiments) wherein the material comprises a drug, a drug and excipient combination, an excipient, an intermediate for the synthesis of a drug, a cell component, a cellular material, a cell, or a plurality of cells. Alternatively, the material may be one useful in agriculture related chemistry, fine chemistry or other chemistry , a radioactive material or any other material used in small or trace amounts (e.g. antibodies, active proteins, nucleic acids) , where exact weighing and distribution of materials is desirable.
In a further particular sub-aspect of the first aspect of the invention, the invention relates to the method according to any one of the preceding aspects, where the position is determined by an optical system, especially including a camera, or a laser detection system, e.g. a laser interferometer; a system for impedance measurement ; or by an acoustic system.
Yet another particular sub-aspect of the first aspect of the invention relates to the method according to any one of the preceding aspects, comprising further determining the shape of the material, especially where liquid droplet materials are used and more especially where solid materials are involved, e.g. in order to allow to determine the par-ticle or crystal shape and/or size in order to allow to conclude on processability e.g. du-ring the manufacture of a pharmaceutical or agrochemistry or cosmetic or chemistry or other formulation.
Another sub-aspect of the first aspect of the invention refers to the method according to any one of the preceding aspects of the first aspect of the invention, comprising further determining the orientation of the particle or droplet.
Another specific sub-aspect of the first aspect of the invention relates to the method according to the preceding paragraph wherein the orientation depends on the effect of the levitation field, acoustic node, or the material in the levitation field, or a combination of two or more of these parameters.
Another sub-aspect of the first aspect of the invention also relates to the method according to any one of the preceding invention aspects, further comprising determining whether the material is in solid form or in liquid form or a combination or mixture thereof (e.g. a suspension or an emulsion or a micelular form) , as well as whether the material is crystalline or amorphous. Aggregates or combinations of the foregoing can also be determined. Another of the sub-aspects of the first aspect of the present invention relates to the method according to any one of the preceding aspects of the first aspect, wherein multiple particles or droplets are introduced into multiple nodes of (one and) the same standing wave simultaneously or sequentially and the determining of the weight of each takes place in parallel.
An important sub-aspect of the first aspect of the invention relates to the method according to any one of the preceding aspects wherein the material is a drug, an excipient, a drug formulation, or intermediate, or placebo or inactive material.
In a sub-aspect of the second aspect of the invention, the method there may comprise determining the weight by a method according to any one of the preceding aspects of the invention.
The method according to the second aspect of the invention, especially according to the preceding paragraph, wherein one or more material particles or droplets are dispensed into one or more further or final destinations is a further sub-aspect of the invention.
Another sub-aspect of the second aspect of the invention relates to the method according to any one of the second invention aspect and sub-aspects thereof wherein the further or final destination is selected based on information comprising one or more of the features selected from the position, the shape, the weight and/or the orientation of the material, especially one or more of a combination of these features including at least the weight.
The method according to the preceding paragraph wherein selecting the further or final destination based upon the weight, polymorphism, size and/or shape of the material is a further sub-aspect of the invention.
The method according to any one of the (sub-) aspects of the second aspect of the invention, comprising dispensing more than one material particle or droplet to the same further or final destination and thus accumulating the material at that destination, especially comprising accumulating up to 10 g of material at the same destination, forms another sub-aspect.
A further sub-aspect of the second invention relates to the method according to any one of the (sub-) aspects thereof mentioned so far, comprising using as the material a drug or drug formulation or placebo.
Another sub-aspect of the second aspect of the invention relates to the method according to any one of its (sub-) aspects mentioned so far, wherein more than one material is used, that is two different material. In particular in the case where the material is a drug, the sub-aspect comprises two or more drugs, and/or in the case of a drug formulation two or more excipients with one or more drugs .
Still another sub-aspect of the second aspect of the invention relates to the method according to any one of its (sub-) aspects mentioned so far, wherein the dispensing of the material is comprising shifting the position of said material so that it enters a device or container as further or final destination, especially comprising using a solid particle as material and shifting the position of the material so that it enters the device which is selected from a tableting and a capsule filling machine, more especially comprising shifting the position of the material into a container which is selected from a capsule, an ampoule, a syringe, a bottle, an infusion container, a sachet, a vial, a spray container or a blister pack, or food product (e.g. nutraceutical) container, each especially for pharmaceutical purposes, respectively.
A further sub-aspect of the second aspect of the invention relates to the method according to any one of its (sub-) aspects mentioned so far, comprising shifting the material to the destination by using multiple sound transducers, applying electrical fields, using gas (e.g. air) streams or blasts, moving the transducers of the levitating wave and/or superimposing a slow acoustic wave oriented in an angle different, for example greater than 0 ° relative to an axis of the levitating wave. For example, in embodiments where the levitating wave is arranged about a vertical axis, a transporting wave may be arrayed at any angle form the vertical axis. Additionally or alternatively shifting the material to the destination may be achieved by weakening or removing the acoustic levitation field, allowing the material to fall into a destination positioned below the material. Combinations of any of the foregoing may be employed.
The method according to any one of the aspects and sub-aspects of the second aspect of the invention, comprising, by shifting the material, supplying specific amounts or dosages into the device or container is another sub-aspect of the second invention aspect.
A further sub-aspect of the second aspect of the invention relates to the method according to any one of its (sub-) aspects mentioned so far, comprising affecting the material using mechanical means to transport it into the device or container.
The method according to any one of the sub-aspects of the second aspect of the invention, comprising using mechanical means to move the receiving device and con-tainer under the material and subsequently disabling the acoustic field to capture the particle in the device, forms an invention sub-aspect.
Yet another sub-embodiment (sub-aspect) of the second aspect of the invention relates to a method according to any one of the aspects or sub-aspects of the second invention mentioned so far, comprising determining the vertical position of the material in order to determine the weight of the material. This is especially important as it allows for precise delivery of amounts of material to containers or ampoules, which may be determined with standard deviations of 1 %or less and are thus much more precisely determined and distributed than in other weigh determination methods.
Another sub-aspect of the second aspect of the invention relates to the method according to any one of its preceding (Sub-) aspects, wherein the position of the material is determined by an optical system or a sound system; especially wherein the position and if part of the respective claim any other feature mentioned is determined with a high-speed microscopic system.
A further sub-aspect of the second aspect of the invention relates to the method according to any one of its preceding (sub-) aspects, comprising providing units of the material (s) with an electric charge of identical polarity in order to inhibit its or their aggre-gation or to allow to move (dispense) them by means of electric field (s) ; or with an electric charge of different polarity in order to promote its or their aggregation or to allow to move (dispense) them by means of electric field (s) .
The method according to any one of the preceding (sub-) aspects of the second invention may comprise controlling one or more parameters selected from the groups
consisting of the temperature, charge, humidity, pressure, and operating conditions of the device housing the material (and/or levitation field) .
The method according to any one of the preceding (sub-) aspects of the second aspect of the invention may comprise determining the weight by calibration with particles or droplets of known weight, e.g. by way of a calibration curve (which may be implemented in programmed form) .
The present invention also, in a third aspect, relates to a device or apparatus appropriate, especially adapted or equipped, e.g. programmed and comprising the means, for executing a method according to any of the invention aspects and sub-aspects defined so far.
In one embodiment of the third aspect of the invention, the invention thus relates to an apparatus (device) comprising an acoustic transducer, an acoustic reflector, and a unit for determining the position of a material which is in the form of a solid particle or a liquid droplet.
This apparatus, as said unit for determining the position of the material, preferably is an optical system, especially comprising a microscope and a high-speed imaging device.
In preferred invention embodiment, the apparatus according to any one of the preceding two paragraphs comprises an input element for the material. Such input element may, for example, be a container with the material (which may already be in particle or droplet form, e.g. in the form of a fluid bed (maintained by gas and/or ultrasound) or spouted bed) , a microfluidic element allowing to feed droplets of material, a micro cup, a funnel or the like.
The apparatus, according to any one of the invention embodiments defined herein before, further preferably comprises a unit or element for shifting the position of the material in an acoustic node.
The apparatus according to any one of the preceding embodiments may, in a further invention embodiment, comprise a unit to collect material positioned, characterized and/or weighed in an acoustic node. This unit may be a device or a container.
The definitions given in the following allow to replace one or more or all general terms of each invention aspect or sub-aspect in which they appear by the more specific definitions, thus defining specific and preferred invention embodiments.
Where a “material” is mentioned, this especially refers to a (relatively small) material portion.
“Particle” in particular means a (under the temperature conditions during application of a method or device according to the invention) solid material that may be a monolithic particle or an aggregate of solid material sub-particles, e.g. a granulate or agglomerate.
“Droplet” in particular means a material with a (under the temperature conditions during application of a method or device according to the invention) liquid continuous matrix which is the sole phase present, or they may comprise solid material (including micelles or liposomes) as non-continuous phase, e.g. as a suspension, or immiscible liquid material, e.g. sub-droplets, e.g. in a water-in-oil or oil-in-water emulsion. Droplets may be disrupted into sub-droplets or they may be united to form larger droplets in the acoustic field or when dispensed into a container or device.
A “micelle” material is especially one comprising supermolecular colloid particles, often including a packet of chain molecules in parallel arrangement, e.g. formed from surface active (amphiphilic) substances.
A “liposome material” is especially a material comprising spherical vesicles having at least one lipid bilayer.
A “viral material” may e.g. be formed from proteins and/or nucleic acids which at least partially correspond to proteins and/or nucleic acids in virus, or genetically modified
variants thereof, or complete virus (which may be inactivated e.g. for vaccination purposes) .
A “cell component” may e.g. comprise membrane vesicles from organelle or the outer membrane of cells, or complete organelles, such as mitochondria.
As a “cell material” , preferably a material comprising one or more cells, such as bacterial or fungal cells, e.g. for vaccination purposes, or e.g. cells from the immune system, such as lymphocytes or phagocytes, e.g. cells allowing to provide monoclonal antibodies, can be meant.
An “optical system” (or optical unit) may comprise a camera, a laser detection system or a high speed (especially microscopic) system.
A “camera” is an optical instrument allowing to record images (single images or sequences of images, e.g. in the form of videos or movies) which may be stored, transmitted to another location, or both. A digital camera is one preferred embodiment. The camera may work with the light of the visible spectrum or with other portions of the electromagnetic spectrum, e.g. UV light.
A “laser detection system” is any laser system that allows to determine distances or positions of materials, or any other properties thereof, such as its surface properties, refractive index, density or the like. Examples are laser measuring devices or laser interferometers. Such systems e.g. allow for the testing of the kind of surface of a solid or liquid material according to the invention embodiments and make it possible to achieve high precision examination of surface topography. Exact imaging is possible e.g. by optical coherence tomography, phase contrast and differential interference contrast microscopy, angle-resolved low-coherence interferometry or phase-contrast X-ray imaging. Laser detection systems can also be used to determine indices of refraction and thermal properties.
A high-speed (especially microscopic) system, including or as part of a camera, may be an especially useful device to determine the position of the material.
In some embodiments of the invention, weight of a particle is determined by determining the vertical position (e.g., location of the particle relative to a lower sound transducer surface or any other reference height or datum) , and comparing the determined location to a calibration plot in order to determine the weight of the particle.
It is also possible to change the strength of the acoustic field in order to change the position of the material to a specific height and to determine the weight by setting it in relation to the strength of the acoustic field, or to use a combination of any of the methods mentioned herein for determining the weight of a material .
Where a material is “dispensed” into one or more final destinations in accordance with one or more of the methods of the invention, this allows for the delivery of a very precise weight amount to the destination, and/or for the delivery of an otherwise characterized material, as mentioned above and below.
A device or container as final destination may comprise a device that allows for the distribution into a unit form of a pharmaceutical preparation, e.g. a container as mentioned in the following, and may e.g. be an ampoule filling, capsule filling or tablet forming device; a container may e.g. be selected from a capsule, an ampoule, a syringe, a bottle, an infusion container, a sachet, a vial and a blister pack.
A device or container as further destination may comprise a device or container that is useful or necessary for some further processing, distribution or handling of the material as an intermediate prior to achieving the final unit form of a pharmaceutical preparation, and may e.g. comprise a filling, transporting, or conditioning device; a con-tainer may e.g. be selected from a well, capsule, ampoule, syringe, bottle, infusion container, sachet, vial and blister.
The shifting the material to the destination by using multiple sound transducers may make use of superimposition of acoustic waves or a tuning of the waves so that to-gether, at least during the dispensing of a material in liquid droplet or solid particle form, sound waves are influenced and added so as to provide a force that drives the material to or above the desired position. This effect may also be obtained by moving the transducers of the levitating wave to a position where the material is to be dispensed to.
Alternatively or in addition, superimposing a slow acoustic wave oriented in an angle different from 0° relative to an axis of the levitating wave may allow for such shift in the position of the material.
Especially if the material is charged (which may, for example, be achieved when it is supplied into the acoustic levitation field employed according to the invention) the particles may also be moved by applying electrical fields, e.g. using two or more electrodes of appropriate charge.
Also by using gas (e.g. air) streams or blasts, a material particle or droplet may experience a force allowing it to be dispensed at or moved to a desired destination.
The dispensing method may (in addition or in combination with any one or more of the other methods appropriate, e.g. as just mentioned) comprise shifting the material to the destination by weakening or removing the acoustic levitation field, allowing the material to fall into a desired destination positioned below the material.
Alternatively or in addition, mechanical means may be used to move the material hovering in the levitation field to a desired destination. These mechanical means may include directly inserting the destination device or container in the field which may lead to a disruption that allows the hovering material to be supplied to the destination. Alternatively, the mechanical means may be robot arms (e.g. equipped with forceps) , plungers, e.g. in rod shape, threads, wires, filaments, sheet-like materials or the like.
The mechanical means may also be a ratchet or conveyor belt, bar or roller that allows to position containers or devices, e.g. vials or ampoules or open capsules or the like, below a position allowing to deliver the material to them, e.g. to a position below the lower confinement of the room in which acoustic levitation is effected, for example through a hole in said lower confinement.
Preferably, the dispensing takes place without need for the material to come into contact with a surface other than that in or at the destination, thus allowing to decrease risks of contamination or material loss on such surfaces.
The material treated or manipulated according to the invention may be supplied with an electric charge of identical polarity in order to inhibit its or their aggregation; or with an electric charge of different polarity in order to promote its or their aggregation. This allows to (e.g. also by moving the material portions towards or away from each other) to form larger particle aggregates or larger droplets. In the case of droplets, it is possible to explode them (e.g. by administration of sufficiently strong sound waves) into smaller droplets and thus to yield smaller material droplets.
The term “dispense” or “dispensing” of a material especially relates to its transfer and deposition at a desired destination. Thus the material can be delivered in a precise amount or with precise knowledge to a desired destination, even without contacting it with any surfaces other than those at the destination.
The term “food product” comprises, for example, a “nutraceutical” (sometimes also called “Functional Food” , “Functional Food product” , “Foodsceutical” , “Medicinal Food” or “Designer Food” ) and, according to the present invention embodiments, is defined as food product (including beverages) suitable for human consumption–the expression comprises any fresh or processed food having a health-promoting and/or disease-preventing property beyond the basic nutritional function of supplying nutrients, including food made from functional food ingredients or fortified with health-promoting additives, especially with an effects in the prophylaxis or treatment of one or more of the disorders mentioned herein, in which a material obtained (especially dispensed) according to the invention is added as an ingredient (especially as additive) as health benefit agent, especially in an effective amount, as well as any partially or totally artificially composed food.
The nutraceuticals can alternatively be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions, suspensions, parenteral products (e.g. intra venous infusions or injects or subcutaneous injects) or the like.
The term “pharmaceutical formulation” (medicament) comprises any type of formulation known in the art. Said formulation may comprise one or more drugs ( “active ingredients” ) with or without (pharmaceutically acceptable) excipient (s) .
Drugs may be selected from antibodies, vaccines, enzymes or small molecule organic drugs or other therapeutically active molecules.
The active ingredient (s) may, for example, be selected from the (non-limiting) group consisting of 5-alpha-reductase inhibitors, 5-aminosalicylates, 5HT3 receptor antagonists, AACE inhibitors with calcium channel blocking agents, ACE inhibitors with thiazides, adamantane antivirals, adrenal cortical steroids, adrenal corticosteroid inhibitors, adrenergic bronchodilators, agents for hypertensive emergencies, agents for pulmonary hypertension, aldosterone receptor antagonists, alkylating agents, allergenics, alpha-glucosidase inhibitors, alternative medicines, amebicides, aminoglycosides, aminopenicillins, aminosalicylates, AMPA receptor antagonists, amylin analogs, analgesic combinations, analgesics, androgens and anabolic steroids, angiotensin converting enzyme inhibitors, angiotensin II inhibitors with calcium channel blockers, angiotensin II inhibitors alone or with thiazidesangiotensin receptor blockers, angiotensin receptor blockers and neprilysin inhibitors, anorectal preparations, anorexiants, antacids, anthelmintics, anti-angiogenic ophthalmic agents, anti-CTLA-4 monoclonal antibodies, anti-infectives, antiadrenergic agents (central) , e.g. with thiazides, antiadrenergic agents (peripheral) , e.g. with thiazides, antiadrenergic agents, centrally acting antiadrenergic agents, peripherally acting antiandrogens, antianginal agents, antiarrhythmic agents, antiasthmatic combinations, antibiotics/antineoplastics, anticholinergics, antiemetics, anticholinergic antiparkinson agents, anticholinergic bronchodilators, anticholinergic chronotropic agents, anticholinergics/antispasmodics, anticoagulants, anticonvulsants, antidepressants, antidiabetic agents, antidiabetic combinations, antidiarrheals, antidiuretic hormones, antidotes, antiemetic/antivertigo agents, antifungals, antigonadotropic agents, antigout agents, antihistamines, antihyperlipidemic agents, antihyperlipidemic combinations, antihypertensive combinations, antihyperuricemic agents, antimalarial agents, antimalarial combinations, antimalarial quinolones, antimetabolites, antimigraine agents, antineoplastic detoxifying agents, antineoplastic interferons, antineoplastics, antiparkinson agents, antiplatelet agents, antipseudomonal penicillins, antipsoriatics, antipsychotics, antirheumatics, antiseptics and germicides, antithyroid agents, antitoxins and antivenins, antituberculosis agents, antituberculosis combinations, antitussives, antiviral agents, antiviral boosters, antiviral combinations, antiviral interferons, anxiolytics, sedatives, hypnotics, aromatase
inhibitors, atypical antipsychotics, azole antifungals, bacterial vaccines, barbiturate anticonvulsants, barbiturates, BCR-ABL tyrosine kinase inhibitors, benzodiazepine anticonvulsants, benzodiazepines, beta blockers with calcium channel blockers, beta blockers with thiazidesbeta-adrenergic blocking agents, beta-lactamase inhibitors, bile acid sequestrants, biologicals, bisphosphonates, bone morphogenetic proteins, bone resorption inhibitors, bronchodilator combinations, bronchodilators, calcineurin inhibitors, calcitonin, calcium channel blocking agents, carbamate anticonvulsants, carbapenems, carbonic anhydrase inhibitor, anticonvulsants, carbonic anhydrase inhibitors, cardiac stressing agents, cardioselective beta blockers, cardiovascular agents, catecholamines, CD20 monoclonal antibodies, CD30 monoclonal antibodies, CD33 monoclonal antibodies, CD52 monoclonal antibodies, central nervous system agents, cephalospo-rins, cerumenolytics, CFTR combinations, CFTR potentiators, chelating agents, chemo-kine receptor antagonists, chloride channel activators, cholesterol absorption inhibitors, cholinergic agonists, cholinergic muscle stimulants, cholinesterase inhibitors, CNS sti-mulants, coagulation modifiers, colony stimulating factors, contraceptives, corticotropin, coumarins and indandionescox-2 inhibitors, decongestants, dermatological agents, di-agnostic radiopharmaceuticals, diarylquinolines, dibenzazepine anticonvulsants, diges-tive enzymes, dipeptidyl peptidase 4 inhibitors, diuretics, dopaminergic antiparkinsonism agents, drugs used in alcohol dependence, echinocandins, EGFR inhibitors, estrogen receptor antagonists, estrogens, expectorants, factor Xa inhibitors, fatty acid derivative anticonvulsants, fibric acid derivatives, first generation cephalosporins, fourth generation cephalosporins, functional bowel disorder agents, gallstone solubilizing agents, gamma-aminobutyric acid analogs, gamma-aminobutyric acid reuptake inhibitors, gastrointes-tinal agents, general anesthetics, genitourinary tract agents, GI stimulants, glucocor-ticoids, glucose elevating agents, glycopeptide antibiotics, glycoprotein platelet inhi-bitors, glycylcyclines, gonadotropin releasing hormones, gonadotropin-releasing hor-mone antagonists, gonadotropins, group I antiarrhythmics, group II antiarrhythmics, group III antiarrhythmics, group IV antiarrhythmics, group V antiarrhythmics, growth hormone receptor blockers, growth hormones, guanylate cyclase-C agonists, H. pylori eradication agents, H2 antagonists, hedgehog pathway inhibitors, hematopoietic stem cell mobilizer, heparin antagonists, heparins, HER2 inhibitors, herbal products, histone deacetylase inhibitors, hormones, hormones/antineoplastics, hydantoin anticonvulsants, hydrazide derivatives, illicit (street) drugs, immune globulins, immunologic agents, im-munostimulants, immunosuppressive agents, impotence agents, in vivo diagnostic bio-
logicals, incretin mimetics, inhaled anti-infectives, inhaled corticosteroids, inotropic agents, insulininsulin-like growth factor, integrase strand transfer inhibitor, interferons, interleukin inhibitors, interleukins, intravenous nutritional products, iodinated contrast media, ionic iodinated contrast media, iron products, ketolides, laxatives, leprostatics, eukotriene modifiers, lincomycin derivatives, local injectable anesthetics, loop diuretics, lung surfactants, lymphatic staining agents, lysosomal enzymes, macrolide derivatives, macrolides, magnetic resonance imaging contrast media, mast cell stabilizers, megliti-nides, metabolic agents, methylxanthines, mineralocorticoids, minerals and electrolytes, miscellaneous agents, miscellaneous analgesics, miscellaneous antibiotics, miscellane-ous anticonvulsants, miscellaneous antidepressants, miscellaneous antidiabetic agents, miscellaneous antiemetics, miscellaneous antifungals, miscellaneous antihyperlipidemic agents, miscellaneous antihypertensive combinations, miscellaneous antimalarials, mis-cellaneous antineoplastics, miscellaneous antiparkinson agents, miscellaneous antipsy-chotic agents, miscellaneous antituberculosis agents, miscellaneous antivirals, miscella-neous anxiolytics, sedatives and hypnotics, miscellaneous bone resorption inhibitors, miscellaneous cardiovascular agents, miscellaneous central nervous system agents, miscellaneous coagulation modifiers, miscellaneous diagnostic dyes, miscellaneous diuretics, miscellaneous genitourinary tract agents, miscellaneous GI agents, miscella-neous hormones, miscellaneous metabolic agents, miscellaneous ophthalmic agents, miscellaneous otic agents, miscellaneous respiratory agents, miscellaneous sex hormo-nes, miscellaneous topical agents, miscellaneous uncategorized agents, miscellaneous vaginal agents, mitotic inhibitors, monoamine oxidase inhibitors, mouth and throat pro-ducts, mTOR inhibitors, mucolytics, multikinase inhibitors, muscle relaxants, mydriatics, narcotic analgesic combinations, narcotic analgesics, nasal anti-infectives, nasal anti-histamines and decongestants, nasal lubricants and irrigations, nasal preparations, na-sal steroids, natural penicillins, neprilysin inhibitors, neuraminidase inhibitors, neuromas-cular blocking agents, neuronal potassium channel openers, next generation cephalo-sporins, nicotinic acid derivatives, NK1 receptor antagonists, NNRTIs, non-cardioselec-tive beta blockers, non-iodinated contrast media, non-ionic iodinated contrast media, non-sulfonylureas, nonsteroidal anti-inflammatory agents, NS5A inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs) , nutraceutical products, nutritional products, ophthalmic anesthetics, ophthalmic anti-infectives, ophthalmic anti-inflammatory agents, ophthalmic antihistamines and decongestants, ophthalmic diagnostic agents, ophthalmic glaucoma agents, ophthalmic lubricants and irrigations, ophthalmic preparations, oph-
thalmic steroids, ophthalmic steroids with anti-infectives, ophthalmic surgical agents, oral nutritional supplements, other immunostimulants, other immunosuppressants, otic anes-thetics, otic anti-infectives, otic preparations, otic steroids, otic steroids with anti-infec-tives, oxazolidinedione anticonvuls, antsoxazolidinone antibiotics, parathyroid hormone and analogs, PCSK9 inhibitors, penicillinase resistant penicillins, penicillins, peripheral opioid receptor antagonists, peripheral vasodilators, peripherally acting antiobesity agents, phenothiazine antiemetics, phenothiazine antipsychotics, phenylpiperazine antidepressants-phosphate binders, plasma expanders, platelet aggregation inhibitors, platelet-stimulating agents, polyenes, potassium sparing diuretics with thiazidespotas-sium-sparing diuretics, probiotics, progesterone receptor modulators, progestinsprolactin inhibitors, prostaglandin D2 antagonists, protease inhibitors, protease-activated recep-tor-1 antagonists, proteasome inhibitors, proton pump inhibitors, psoralens, psychothe-rapeutic agents, psychotherapeutic combinations, purine nucleosides, pyrrolidine anti-convulsants, quinolones, radiocontrast agents, radiologic adjuncts, radiologic agents, radiologic conjugating agents, radiopharmaceuticals, recombinant human erythropo-ietins, renin inhibitors, respiratory agents, respiratory inhalant products, rifamycin deri-vatives, salicylates, sclerosing agents, second generation cephalosporins, selective estrogen receptor modulators, selective immunosuppressants, selective phosphodies-terase-4 inhibitors, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, serotoninergic neuroenteric modulators, sex hormone combinations, sex hormones, SGLT-2 inhibitors, skeletal muscle relaxant combinations, skeletal mus-cle relaxants, smoking cessation agents, somatostatin and somatostatin analogs, sper-micides, statins, sterile irrigating solutions, streptomyces derivatives, succinimide anti-convulsants, sulfonamides, sulfonylureas, synthetic ovulation stimulants, tetracyclic antidepressants, tetracyclines, therapeutic radiopharmaceuticals, therapeutic vaccines, thiazide diuretics, thiazolidine diones, thioxanthenes, third generation cephalosporins, thrombin inhibitors, thrombolytics, thyroid drugs, TNF alfa inhibitors, tocolytic agents, topical acne agents, topical agent, stopical anesthetics, topical anti-infectives, topical anti-rosacea agents, topical antibiotics, topical antifungals, topical antihistamines, topical antineoplastics, topical antipsoriatics, topical antivirals, topical astringents, topical debri-ding agents, topical depigmenting agents, topical emollients, topical keratolytics, topical non-steroidal anti-inflammatories, topical photochemotherapeutics, topical rubefacient, topical steroids, topical steroids with anti-infectives, triazine anticonvulsants, tricyclic antidepressants, trifunctional monoclonal antibodies, ultrasound contrast media, upper
respiratory combinations, urea anticonvulsants, urea cycle disorder agents, urinary anti-infectives, urinary antispasmodics, urinary pH modifiers, uterotonic agents, vaccine com-binations, vaginal anti-infectives, vaginal preparations, vasodilators, vasopressin anta-gonists, vasopressors, VEGF/VEGFR inhibitors, viral vaccines, viscosupplementation agents, vitamin and mineral combinations, and vitamins. These diseases are from the Drug Class Database of the FDA and are non-limiting.
The present invention relates also to pharmaceutical formulations (pharmaceutical compositions) that comprise an active ingredient as or included in a material obtained (e.g. dispensed) according to the invention and that can be used especially in the treatment of the diseases mentioned herein.
The material of the present invention may be used, for example, for the preparation of pharmaceutical compositions that comprise a pharmaceutically effective amount of a material.
The active ingredient in said material may be present in free form or in the form of a pharmaceutically acceptable salt, solvate, hydrate or polymorph, or in admixture with a significant amount of one or more inorganic or organic, solid or liquid, pharmaceutically acceptable excipients (carriers) .
Compositions for enteral administration, such as nasal, buccal, rectal or, especially, oral administration, and for parenteral administration, such as intravenous, intramuscular or subcutaneous administration, to warm-blooded animals, especially humans, are especially preferred. The compositions comprise the active ingredient alone or, preferably, together with a pharmaceutically acceptable excipient (carrier) . The dosage of the active ingredient depends upon the disease to be treated and upon the species, its age, weight, and individual condition, the individual pharmacokinetic data, and the mode of administration.
The pharmaceutical compositions comprise from approximately 0.0001%to approximately 100% (%referring to weight percent) active ingredient, single-dose administration forms comprising in the preferred embodiment from approximately 0.001%to approximately 100%active ingredient and forms that are not of single-dose
type comprising in the preferred embodiment from approximately 5%to approximately 20%active ingredient. Unit dose forms are, for example, coated and uncoated tablets, ampoules, vials, suppositories, sachets, sprinkles, spray containers or capsules. Further dosage forms are, for example, ointments, creams, pastes, foams, tinctures, sprays, etc. Examples are capsules or tablets or ampoules containing from about 0.0001 mg to about 1.0 g, e.g. from 0.001 to 5 mg material dispensed according to the invention embodiments.
The pharmaceutical compositions of the present invention are, taking reference to the inventive dispensing, otherwise prepared in a manner known per se, for example by means of conventional mixing, granulating, coating, dissolving or lyophilizing processes or by mixing using a method or device according to the invention.
Preference is given to the use of solutions of the material with the active ingredient, and also suspensions or dispersions, especially isotonic aqueous solutions, dispersions or suspensions which, for example in the case of lyophilized compositions comprising the active ingredient alone or together with a carrier can be made up before use. The pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes. The said solutions or suspensions may comprise viscosity-increasing agents or solubilizers, such as sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone or gelatin.
Suspensions in oil comprise as the oil component the vegetable, synthetic or semi-synthetic oils customary for injection purposes. There may be mentioned as such especially liquid fatty acid esters that contain as the acid component a long-chained fatty acid having from 8 to 22, especially from 12 to 22, carbon atoms, for example lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brasidic acid or linoleic acid, if desired with the addition of anti-oxidants, for example vitamin E, β-carotene or 3, 5-di-tert-butyl-4-hydroxytoluene. The alcohol component of those fatty acid esters has a maximum of 6 carbon atoms and is a
mono-or poly-hydroxy, for example a mono-, di-or tri-hydroxy, alcohol, for example methanol, ethanol, propanol, butanol or pentanol or the isomers thereof, but especially glycol and glycerol. The following examples of fatty acid esters are therefore to be men-tioned: ethyl oleate, isopropyl myristate, isopropyl palmitate, "Labrafil M 2375" (polyoxy-ethylene glycerol trioleate, Gattefossé, Paris) , "Miglyol 812" (triglyceride of saturated fatty acids with a chain length of C8 to C12, Hüls AG, Germany) , but especially vegetable oils, such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.
Injection compositions are prepared in customary manner under sterile conditions; the same applies also to introducing the compositions into ampoules or vials and sealing the containers.
Pharmaceutical compositions for oral administration which are also especially preferred can be obtained by combining the material with the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture, if desired or necessary, after the addition of appropriate excipients, into tablets, dragée cores or capsules. It is also possible for them to be incorporated into plastics carriers that allow the active ingredients to diffuse or be released in measured amounts.
Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and binders, such as starch pastes using for example corn, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, and/or carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate. Excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol. Dragée cores are provided with suitable, optionally enteric, coatings, there being used, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents, or, for the preparation of enteric coatings, solutions of suitable cellulose
preparations, such as ethylcellulose phthalate or hydroxypropylmethylcellulose phtha-late. Capsules are dry-filled capsules made of gelatin or HPMC and soft sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The dry-filled capsules may comprise the active ingredient in the form of granules, for example with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and if desired with stabilizers. In soft capsules the active ingredient is preferably dissolved or suspended in suitable oily excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilizers and/or antibacterial agents to be added. Dyes or pigments may be added to the tablets or dragée coatings or the capsule casings, for example for identification purposes or to indicate different doses of active ingredient.
Tablet cores can be provided with suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations.
Pharmaceutical compositions for oral administration also and especially include hard capsules consisting of gelatin, and also soft, sealed capsules consisting of gelatin and a plasticizer. The hard capsules may contain the active ingredient in the form of granules, for example in admixture with fillers, binders, and/or glidants, and optionally stabilizers. In soft capsules, the active ingredient is preferably dissolved or suspended in suitable liquid excipients, to which stabilizers and detergents may also be added.
Pharmaceutical compositions suitable for rectal administration are, for example, suppositories that consist of a combination of the active ingredient and a suppository base.
For parenteral administration, aqueous solutions of an active ingredient in water-soluble form, for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers, are especially suitable. The active ingredient, optionally together with excipients, can also be in the form of a lyophilizate
and can be made into a solution before parenteral administration by the addition of suitable solvents.
Solutions such as are used, for example, for parenteral administration can also be employed as infusion solutions.
As used herein, the term “excipient” especially refers to any pharmaceutically or nutraceutically acceptable carrier material as already mentioned and also and includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents) , isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combi-nations thereof, as would be known to those skilled in the art. Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
The term "a therapeutically effective amount"especially refers to an amount of the material obtainable according to the present invention (especially the active ingredient forming it or comprised in it) that will elicit the biological or medical response of a subject suffering from a disease or disease symptoms, including ameliorating the status of a subject suffering from said disease, alleviating the disease or one or more of its symptoms, or preventing the disease, or the like. As used herein, the term “subject” refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female) , cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is in particular a human.
The dosage of a material obtained (e.g. dispensed) or characterized according to the invention embodiments in pharmaceutical preparations and food products may vary according to the patient’s needs, status and condition. For example, a daily dosage (which may be split up into two or more, e.g. up to three dosage units) may be in the range from 0.0001 mg to 5000 mg, such as from 0.001 to 5 mg, e.g. from 0.001 to 1 mg.
Placebo formulations may comprise solely the excipient material (s) and may be useful in the placebo treatment or in clinical trials.
Diseases (including disorders) may, for example, be selected from the group consisting of infectious and parasitic diseases, especially lower respiratory tract infections, diarrhea, AIDS, tuberculosis, and malaria; neuropsychiatric conditions, e.g. depression; injuries, especially motor vehicle accidents, cardiovascular diseases, principally heart attacks and stroke, premature birth and other perinatal deaths, gastrointestinal disorders, and cancer. Any disease or disorder encompassed by these general terms or any other disease or disorder may be comprised.
Where “intermediate” is referred to, this relates to any compound which is used as starting material or intermediate in the synthesis of a final drug molecule. Examples are organic low molecular weight compounds, enzymes, antibodies or specifically binding parts thereof, nucleic acids or nucleic acid derivatives, such as siRNA, or the like, especially selected from the active ingredients mentioned above.
In accordance with the foregoing, the present invention also comprises the following embodiments which can be claimed:
(1) A material obtained (especially dispensed) according to the invention for use in the diagnostic or especially therapeutic (including prophylactic) treatment of an animal, preferably a mammal, especially a human; especially of any one or more of the particular disorders set forth hereinbefore and hereinafter.
(2) A pharmaceutical or neutraceutical composition comprising a material obtained (es-pecially dispensed) according to a method of the invention as active ingredient together with a pharmaceutically acceptable diluent or carrier, especially for use in the therapeutic and/or prophylactic treatment of a disease or disorder, e.g. mentioned herein.
(3) A method for the treatment of a disorder, especially any one or more disorders, e.g. set forth herein, in a subject in need of such treatment, comprising administering a pharma-ceutically effective amount of a material obtained (especially dispensed) according to a method of the invention, especially to an individual in need thereof.
(4) The use of a material obtained (especially dispensed) according to a method of the invention, for the manufacture of a medicament or food supplement for the treatment or prevention of a disease or disorder e.g. as mentioned herein;
(5) A method as defined above comprising co-administration, e.g. concomitantly or in sequence, a therapeutically effective amount of a material obtained (especially dispensed) according to a method of the invention, and a different pharmaceutically active compound and/or a pharmaceutically acceptable salt thereof, said different pharmaceutically active compound and/or salt thereof being especially for use in the treatment of any one or more of the disorders set forth hereinbefore or hereinafter.
(6) A combination product comprising a therapeutically effective amount of a material obtained (especially dispensed) according to a method of the invention, and a different pharmaceutically active compound and/or a pharmaceutically acceptable salt thereof, said second pharmaceutically active compound being especially for use or of use in the treatment of any one or more of the particular disorders set forth hereinbefore.
The Figures show exemplary invention embodiments as follows:
Fig. 1 shows a schematic representation of an embodiment of acoustic levitation of a particle.
Fig. 2 is a graph showing the distribution of sound pressure level (in dB) and the vertical position in an embodiment of an acoustic levitation field relative to the distance from a node 4 in mm.
Fig. 3 is a calibration curve for an embodiment of the invention for a determination of weight of a particle and its vertical position in an acoustic levitation field relative to the position with maximum sound pressure (the “datum” ) .
Fig. 4 schematically represents an apparatus according to an embodiment of the invention that allows for the touch-free transport (dispensing) of a material to a desired destination, here capsule halves.
Fig. 5 schematically illustrates, in an embodiment of the invention, how material levitation is detected and converted to weight measurement.
Examples: The following examples illustrate the invention without limiting its scope.
In Fig. 1, the principle of acoustic levitation, according to various embodiments of the invention, is represented. A transducer 1 and a reflector 2 are set up in a distance that allows an acoustic standing wave to be formed between them. A material 3 (here in a non-limiting way a particle) is held in a hovering position (in levitation) above a node 4 (capture node, positive sound pressure area) of the acoustic standing wave, remote from the antinode 5 (rejection node, negative sound pressure area) . Also the corresponding sound velocity wave 6 and the sound pressure wave 7 are represented schematically. The material 3 is kept in the upper area of the node 4 as there, the lower the position, the higher the pressure to keep it in its hovering position is. If the particle is (e.g. by shift of the position of the node or by decreasing the energy of the sound wave) reaching the lower half of the node 4, it may drop through this lower part (with declining pressure) and the antinode 5 and then be held by the next node 4 in a hovering position or drop e.g. through a hole in the transducer to a desired destination. This allows for one way to deliver a material without touching (and thus e.g. contaminating or otherwise influencing the surface of it) it to a desired destination.
Fig. 2 shows an example for the measured sound level for an actually established standing acoustic wave (the sound pressure level profile in the particle levitator for one set of operating conditions actually used) . Node 4 and antinode 5 of the actual sound pressure wave 7 and their height relative to the datum (amaximum sound pressure position, i.e. a node) are shown. The sound pressure level can, for example, be determined with a sound pressure calibration sensor 15) as shown in Fig. 4.
In Fig. 3, the result of levitation height and corresponding weight determination of particles are shown. The particles levitate at different heights depending on their size and hence weight. The particles levitated at the height at which acoustic pressure forces are balanced by weight. Measurements of the sound pressure level in the particle levitator in Fig. 2. In an ideal case we would expect the sound pressure level to be perfectly sinusoidal. As real world effects are observed such as the presence of harmonics and other non-linearities which puts higher demands on a theoretical
relationship to predict the sound pressure level. Therefore, in the present case a calibration curve (represented in Fig. 3) was established by actually determining the position relative to a datum (apredetermined location–in this case the surface of the transducer) for a range of particles with known weights and generating a calibration plot.
However, alternatively also theoretical predictions of the weight/height (position) or the material particles can be used (e.g. based on determination of the sound pressure level at specific heights) , or combinations or calibration and theoretical prediction.
Note that instead of particles also droplets can be used both for calibration as well as for the determination of the weight of material portions (particles or droplets) .
In order to perform a calibration, in the example represented in Fig. 3 several different particle diameters were levitated within the acoustic particle levitator at the same time. The nominal particle diameters used were 20 microns (μm) , 50 μm and 100μm. The sizes of all three particle species are known to within 1%because they are calibration standard particles and hence can be treated as particles of known weight and density. (These particles are NIST-standard particles and exact diameters and density–and hence weight -are provided by the manufacturer) . These particle diameters were chosen to span the particle size range that the experimentators were interested in and do not represent the maximum or minimum particle diameters that can be levitated.
By imaging with an optical system 14 (see e.g. the representations in Figs. 4 and 5, the levitation heights tabulated in Table 1 were determined:
Table 1. Particle levitation height versus weight
These experimental values are represented in Fig. 3 in a logarithmic scale, where also the resulting exponential function is represented. Particle levitation height is shown on the horizontal axis in mm (origin is arbitrary) , and weight is shown on the vertical axis.
The power law used to attain the plot in Fig. 3 results in a fit parameter that is very nearly 1.0 indicating an excellent fit. This is a 2 parameter to 3 data points function which means that there is one more degree of freedom in the model. Consequently it would be possible for the curve fit to not pass perfectly through all three points. For a parabolic fit, the fit parameter would be exactly 1.0 because there would be 3 degrees of freedom in the data and 3 degrees of freedom in the model. Table 1 shows the known weight of the particles in column 2 and the weight determined from the regression in column 3. Column 4 shows the absolute value of the percentage error between the known weight and the weight determined by the regression. The average error for this measurement is 5.3%.
By supplying two particles of different sizes (in this case, ibuprofen) , it could be shown that the larger (heavier) particle has a lower position in the same node than the smaller (less heavy) particle (not shown) .
Fig. 4 shows an example for an apparatus according to the invention that allows to both measure the material portion, e.g. particle, weight and to dispense the material to a devi-ce or container, here to capsule halves 22 on an output device 21, here in the exemplary form of a conveyor or collection device. The standing wave is produced by sound transducers 1, (here illustrated as an upper and lower transducer, but alternatively one of which may also be a sound reflector 2.
The material (e.g. a particle or droplet of a drug material, such as an ibuprofen particle) is provided from a material supply 8 (here represented as an arrow) to the acoustic trap sites 11 via an input dispensing tube or channel 10, The acoustic trap sites 11 correspond to nodes 4 in Fig. 1 and Fig. 2. In many embodiments, by varying the strength of the acoustic levitation field, the particles may be delivered to specific trap sites 11. Arrow 12 represents the direction of particle flow in the Fig.
An optional optical system (not shown) may be positioned near particle introduction and allows to control the particle entry if desired. An additional or alternative optional optical system (not shown) may be positioned below a particle outdrop tube 19
The optical system 14 (e.g. a camera) allows to determine the position of a material portion (e.g. particle) at node 4 and thus provides the information required to determine its weight (e.g. from a calibration curve as shown in Fig. 3 which can be programmed into a computer 25 as shown in Fig. 5, for example) . A sound pressure level calibrations sensor 15 may be provided e.g, in order to allow for calibration based on sound pressure and/or to control the sound pressure if for example by lowering the sound intensity (energy) or by switching it off the particle (s) are to be dispensed to a desired destination, such as the capsule halves 22 shown here paradigmatically. This may be controlled by a detection unit (not shown) or the particle may simply fall through, e.g., outdrop tube 19 through which the material portion, e.g. particle, may fall without contacting it. The output may be controlled by an optional optical system (not shown) which may interface with a detection unit 18..
Defective material (e.g. of undesired shape, weight or density) may (for example by use of a sound wave used in perpendicular direction to the wave represented by the trap sites 11 in the Figure) dispensed (transferred) to a collection vessel 17 under the control of the detection unit (e.g. extraction tube) 18 for defective material.
Alternatively (not shown) , the dispensing of material portions (e.g. particles or droplets) may take place laterally (horizontally, e.g. perpendicular to the vertical wave axis) to a position other than outdrop tube 19, e.g. by electrical fields (then the material portions are preferably provided in a charged form) or superimposed sound wave allowing to shift the particles laterally (which can also be done as depicted here for defective particles only) .
Fig. 5 shows another schematic representation of a device forming an invention embodiment for weighing a material particle 3, also schematically depicting the sound pressure wave 7 and showing the particle position relative to a datum 24 which is the po-sition of maximum sound pressure in the corresponding node. A camera is shown as an
example of an optical system 14, and allows for the position determination of the material particle 3, here represented as levitation height X above the datum 24, and computer 25 allows for determining the weight of the particle 3 and for controlling the device.
While various embodiments have been described above, it should be understood that they have been presented by way of example only, and not limitation. Thus, the breadth and scope of a preferred embodiment should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.
Claims (44)
- A method of determining the weight of a material which is in the form of a solid particle or a liquid droplet, comprising introducing said material into an acoustic levitation field, so that it is positioned and kept in position by an acoustic node of a standing wave in the acoustic levitation field, determining the position of the material and using the position information to determine the weight of the material.
- The method according to claim 1, wherein the material particle or droplet has a weight in the range from 0.1 ng to 5 g, e.g. from 0.1 ng to 100 mg, in particular from 1 ng to 5 or 1 mg.
- The method according to any one of claims 1 or 2, wherein the solid material is a result of liquid material comprising a solution or dispersion, including a suspen-sion of a solid material in a solvent or solvent mixture or an emulsion of a liquid material in a solvent or solvent mixture that is not miscible with the solvent.
- The method according to claim 3, further comprising evaporating the solvent and forming the solid material in dry form.
- The method according to claim 1 or claim 2 wherein the material is solid and can be pulverous, crystalline, amorphous, a granule, an agglomerate of particles, a mixture of solid states, micelle material, liposome material, a viral material, a cell component or cell material.
- The method according to any one of claims 1 to 5 where the material comprises a drug, a drug and excipient combination, an excipient, an intermediate for the synthesis of a drug, a cell component or a cell, a food product, nutraceutical, or a material useful in agriculture related chemistry, other chemistry, . fine chemistry, a radioactive material or another material used in trace amounts,
- The method according to any one of claims 1 to 6, wherein the position is determined by an optical system.
- The method according to any one of claims 1 to 7, comprising further determining the shape of the material, especially where liquid droplet materials are used or alternatively where solid particle materials are used.
- The method according to any one of claims 1 to 8, comprising further determining the orientation of the particle or droplet.
- The method according to claim 9 wherein the orientation depends on the effect of the levitation field, acoustic node, or the material in the levitation field, or a combination of two or more of these parameters.
- The method according to any one of claims 1 to 10, further comprising determining whether the material is in solid or in liquid form or mixture or an aggregate or a combination of two or more of these forms.
- The method according to any one of claims 1 To 11, further comprising determining whether the material is in crystalline or amorphous form, or a combination thereof.
- The method according to any one of claims 1 to 12, wherein multiple particles or droplets are introduced into multiple nodes of the same standing wave simultane-ously or sequentially and the determining of the weight of each takes place in parallel.
- The method according to any one of claims 1 to 13 wherein the material is a drug or a drug formulation, or placebo or intermediate.
- A method of dispensing a material in the form of a solid particle or a liquid droplet or mixture, comprising introducing said material into an acoustic levitation field, so that it is positioned and kept in position by an acoustic node of a standing wave in the acoustic levitation field, determining information on any one or more features selected from the position, the shape, the weight and the orientation of the material and using the obtained feature to dispense the material into a final destination.
- The method according to claim 15, comprising determining the weight by a method according to any one of claims 1 to 14.
- The method according to any one of claims 15 or 16, wherein one or more mate-rial particles or droplets are dispensed into one or more final destinations.
- The method according to any one of claims 14 to 17, wherein the final destination is selected based on the information one or more of the features selected from the position, the shape, the weight and the orientation of the material.
- The method according to claim 18 wherein the final destination is selected based on the weight, polymorphism, size and shape of the material.
- The method according to any one of claims 14 to 18, comprising dispensing more than one material particle or droplet to the same final destination and thus accumulating the material at that destination.
- The method according to claim 20, comprising accumulating up to 10 g of mate-rial at the same destination.
- The method according to any one of claims 14 to 20, comprising using as the material a drug or drug formulation or placebo.
- The method according to any one of claims 14 to 22, wherein more than one ma-terial is used. The method according to 22, wherein the more than one material is a drug or excipient, or both.
- The method according to any one of claims 14 to 22, wherein the dispensing of the material comprises shifting the position of said material so that it enters a device or container as destination.
- The method according to claim 24, comprising using a solid particle as material and shifting the position of the material so that it enters the device which is selected from a tableting and a capsule filling machine.
- The method according to claim 24, comprising shifting the position of the material into a container which is selected from a capsule, an ampoule, a syringe, a bottle, an infusion container, a sachet, a vial, a spray container or a blister pack.
- The method according to any one of claims 14 to 26, comprising shifting the material to the destination by using multiple sound transducers, applying electrical fields, using a gas stream or blast, moving the transducer (s) of the levitating wave or superimposing a slow acoustic wave oriented in an angle different from 0° relative to the levitating wave, or combinations thereof.
- The method according to any one of claims 14 to 56, comprising shifting the material to the destination by weakening or removing the acoustic levitation field, and allowing the material to fall into a destination positioned below the material.
- The method according to any one of claims 14 to 26, comprising, by shifting the material, supplying specific amounts or dosages into the device or container.
- The method according to any one of claims 14 to 24, comprising affecting the material using mechanical means to transport it into the device or container.
- The method according to any one of claims 14 to 24, comprising using mechanical means to move the receiving device and container under the material and subsequently disabling the acoustic field to capture the particle in the device.
- The method according to any one of claims 1 to 26, comprising determining the vertical position of the material in order to determine the weight of the material.
- The method according to any one of claims 1 to 27, wherein the position of the material is determined by an optical system or a sound system, or both.
- The method according to any one of claims 1 to 28, wherein the position of the material is determined with a high-speed microscopic system.
- The method according to any one of claims 1 to 34, comprising providing units of the material (s) with an electric charge of identical polarity in order to inhibit its or their aggregation.
- The method according to any one of claims 1 to 34, comprising providing units of the material (s) with an electric charge of different polarity in order to promote its or their aggregation.
- The method according to any one of claims 1 to 34, comprising controlling one or more parameters selected from the group consisting of temperature, charge, humidity, pressure, operating conditions of the device housing the material, characteristics of the levitation field, and combinations thereof.
- The method according to any one of claims 1 to 37, comprising determining the weight by calibration with particles or droplets of known weight.
- An apparatus, for carrying out a method according to any one of claims 1 to 37, comprising an acoustic transducer, an acoustic reflector, and a unit for determining the position of a material which is in the form of a solid particle or a liquid droplet.
- The apparatus according to claim 39, wherein the unit for determining the position is an optical system.
- The apparatus according to claim 40 wherein the optical system comprises a microscope and a high-speed imaging device.
- The apparatus according to any one of claims 38 to 41, comprising a unit or element for shifting the position of the material in an acoustic node.
- The apparatus according to any one of claims 38 to 42, comprising a unit to collect material positioned and/or weighed in an acoustic node.
- The apparatus according to claim 43, wherein the unit to collect material is a device or a container.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/094697 WO2017084012A1 (en) | 2015-11-16 | 2015-11-16 | Acoustic material weighing and manipulation |
PCT/IB2016/056846 WO2017085613A1 (en) | 2015-11-16 | 2016-11-14 | Weighing and characterizing materials by acoustic levitation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/094697 WO2017084012A1 (en) | 2015-11-16 | 2015-11-16 | Acoustic material weighing and manipulation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017084012A1 true WO2017084012A1 (en) | 2017-05-26 |
Family
ID=57392014
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/094697 WO2017084012A1 (en) | 2015-11-16 | 2015-11-16 | Acoustic material weighing and manipulation |
PCT/IB2016/056846 WO2017085613A1 (en) | 2015-11-16 | 2016-11-14 | Weighing and characterizing materials by acoustic levitation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2016/056846 WO2017085613A1 (en) | 2015-11-16 | 2016-11-14 | Weighing and characterizing materials by acoustic levitation |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO2017084012A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107591066A (en) * | 2017-10-24 | 2018-01-16 | 西北工业大学 | A kind of controllable acoustic levitation experimental provision of more physical environments |
CN109269630A (en) * | 2018-08-30 | 2019-01-25 | 哈尔滨工业大学(威海) | A kind of underwater ultrasound suspension field measurement device and application method |
CN109695437A (en) * | 2018-12-27 | 2019-04-30 | 西南石油大学 | A kind of gas well ultrasound suspending liquid discharging gas producing system and implementation method |
WO2019114891A3 (en) * | 2017-12-13 | 2019-08-08 | Universität Hamburg | Method and device for coating an individual particle |
WO2020232348A1 (en) * | 2019-05-15 | 2020-11-19 | The Regents Of The University Of California | Omnidirectional spiral surface acoustic wave generation |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115970784A (en) * | 2018-07-20 | 2023-04-18 | 布赖顿技术有限责任公司 | Method and apparatus for determining droplet mass from a sample collected from a liquid droplet dispensing system |
JP6839227B2 (en) * | 2019-05-31 | 2021-03-03 | Dgshape株式会社 | Droplet attachment device |
JP2023512659A (en) * | 2020-01-27 | 2023-03-28 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | Devices, systems and methods for in vitro screening of complex biological fluids |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5810155A (en) * | 1993-07-12 | 1998-09-22 | Kaijo Corporation | Object levitating apparatus object transporting apparatus and object levitating bearing along with an object levitating process and object transporting process |
JP2005239391A (en) * | 2004-02-27 | 2005-09-08 | Toyota Industries Corp | Object levitation device and object levitation carrying device |
US20120197005A1 (en) * | 2011-01-31 | 2012-08-02 | Uchicago Argonne, Llc | Containerless synthesis of amorphous and nanophase organic materials |
CN202935948U (en) * | 2012-08-15 | 2013-05-15 | 吉林大学 | Ultrasonic wave and air floatation mixed non-contact automatic conveying device |
CN104085691A (en) * | 2014-07-30 | 2014-10-08 | 华东理工大学 | Ultrasonic suspension conveying device |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4420977A (en) * | 1982-03-15 | 1983-12-20 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Acoustic rotation control |
US5036944A (en) * | 1986-03-24 | 1991-08-06 | Intersonics Incorporated | Method and apparatus for acoustic levitation |
US6109098A (en) | 1998-06-30 | 2000-08-29 | Doukhin Dispersion Technology, Inc. | Particle size distribution and zeta potential using acoustic and electroacoustic spectroscopy |
US6216091B1 (en) | 1998-09-25 | 2001-04-10 | Panametrics, Inc. | Ultrasonic measurement system with molecular weight determination |
CA2432067A1 (en) | 2002-06-14 | 2003-12-14 | National Research Council Of Canada | Ultrasonic apparatus and methods for the monitoring of melting, mixing, and chemical reaction processes |
KR101473532B1 (en) | 2012-11-20 | 2014-12-16 | 지에스칼텍스 주식회사 | Recombinant microorganism having enhanced butanol producing ability and method for producing butanol using the same |
-
2015
- 2015-11-16 WO PCT/CN2015/094697 patent/WO2017084012A1/en active Application Filing
-
2016
- 2016-11-14 WO PCT/IB2016/056846 patent/WO2017085613A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5810155A (en) * | 1993-07-12 | 1998-09-22 | Kaijo Corporation | Object levitating apparatus object transporting apparatus and object levitating bearing along with an object levitating process and object transporting process |
JP2005239391A (en) * | 2004-02-27 | 2005-09-08 | Toyota Industries Corp | Object levitation device and object levitation carrying device |
US20120197005A1 (en) * | 2011-01-31 | 2012-08-02 | Uchicago Argonne, Llc | Containerless synthesis of amorphous and nanophase organic materials |
CN202935948U (en) * | 2012-08-15 | 2013-05-15 | 吉林大学 | Ultrasonic wave and air floatation mixed non-contact automatic conveying device |
CN104085691A (en) * | 2014-07-30 | 2014-10-08 | 华东理工大学 | Ultrasonic suspension conveying device |
Non-Patent Citations (1)
Title |
---|
ANONYMOUS.: "Experiment of Sound Levitation", 13 November 2013 (2013-11-13), Retrieved from the Internet <URL:http://wenku.baidu.com/link?url=QZ5Vo3xJFs9WoDsTWZ-xLiXwtJ0lK9YPEd4jHLIEl42p9NS1nYR8HgkqJOZAs59mvtZuOxcyOGeWBrt02v23X7kewYunIrxt> [retrieved on 20160615] * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107591066A (en) * | 2017-10-24 | 2018-01-16 | 西北工业大学 | A kind of controllable acoustic levitation experimental provision of more physical environments |
WO2019114891A3 (en) * | 2017-12-13 | 2019-08-08 | Universität Hamburg | Method and device for coating an individual particle |
CN109269630A (en) * | 2018-08-30 | 2019-01-25 | 哈尔滨工业大学(威海) | A kind of underwater ultrasound suspension field measurement device and application method |
CN109269630B (en) * | 2018-08-30 | 2021-07-02 | 哈尔滨工业大学(威海) | Underwater ultrasonic suspension field measuring device and using method |
CN109695437A (en) * | 2018-12-27 | 2019-04-30 | 西南石油大学 | A kind of gas well ultrasound suspending liquid discharging gas producing system and implementation method |
WO2020232348A1 (en) * | 2019-05-15 | 2020-11-19 | The Regents Of The University Of California | Omnidirectional spiral surface acoustic wave generation |
Also Published As
Publication number | Publication date |
---|---|
WO2017085613A4 (en) | 2017-07-20 |
WO2017085613A1 (en) | 2017-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017084012A1 (en) | Acoustic material weighing and manipulation | |
Tran et al. | Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs | |
Jacob et al. | Emerging role of nanosuspensions in drug delivery systems | |
JP6147811B2 (en) | Inhalable composition with improved bioavailability | |
Lühder et al. | Novel drug delivery systems tailored for improved administration of glucocorticoids | |
Patil et al. | Inhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC) | |
ES2878403T3 (en) | Method for preparing spray dried homogeneous solid amorphous drug dispersions using modified spray drying apparatus | |
KR20200015828A (en) | Inhalable pharmaceutical compositions | |
JP7228503B2 (en) | Dosing regimen for omitted doses of long-acting injectable paliperidone ester | |
Weng et al. | Cocrystal engineering of itraconazole with suberic acid via rotary evaporation and spray drying | |
WO2016041250A1 (en) | Inflammation targeted neutrophil granulocyte drug delivery system and use thereof | |
La Zara et al. | Controlled pulmonary delivery of carrier-free budesonide dry powder by atomic layer deposition | |
CN1913871A (en) | Nanosuspensions of anti-retroviral agents for increased central nervous system delivery | |
JP7236485B2 (en) | Method for producing composite particles for inhalation using three-fluid nozzle | |
CN106132970A (en) | Borate and its pharmaceutical preparation | |
Hadiwinoto et al. | Integrated continuous plug-flow crystallization and spray drying of pharmaceuticals for dry powder inhalation | |
CN106983719A (en) | A kind of docetaxel polymer nano micelle injection, its preparation method and its application in tumor is prepared | |
Shaji et al. | Current Development in the Evaluation Methods of Pulmonary Drug Delivery System. | |
CN102225058A (en) | Oseltamivir phosphate dry powder inhalations and preparation method thereof | |
WO2022125882A1 (en) | Oral capsule cannabinoid formulations | |
CN103717239B (en) | It is suitable for the pharmaceutical composition of the Oxavidin of suction | |
CN104116712B (en) | A kind of hollow property nanometer aggregated particle of interferon albumin for pulmonary administration | |
CN101597312A (en) | Dimension formyl A acyl cytosine arabinoside conjugate and pharmacome, its preparation method and application | |
Budiman et al. | Amorphous Solid Dispersion as Drug Delivery Vehicles in Cancer | |
WO2022235750A1 (en) | Delivery of cellular material and other material as a dry powder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15908509 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15908509 Country of ref document: EP Kind code of ref document: A1 |